Antimalarial hexahydropyrimidine analogues

Abstract

A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives substituted at the 6-position by an arylphenyl or heteroarylphenyl moiety, which are potent inhibitors of the growth and proliferation of the Plasmodium falciparum parasite in human blood, are useful as pharmaceutical agents, particularly in the treatment of malaria.

Description

[Technical field]

[0001] The present invention relates to a class of heterocyclic compounds and their use in therapy. More particularly, the present invention relates to pharmacologically active substituted hexahydropyrimidine derivatives and analogues thereof. These compounds are potent inhibitors of the growth and proliferation of the Plasmodium falciparum parasite in human blood and are therefore useful as pharmaceutical agents, particularly in the treatment of malaria. [Background technology]

[0002] Malaria is a devastating, mosquito-borne infectious disease caused by parasites of the genus Plasmodium. Based on 2019 data, approximately 229 million cases resulting in approximately 409,000 deaths are reported annually. Approximately 80% of cases occur in sub-Saharan Africa, mainly in young children (under 5 years of age).

[0003] Thus, the compounds according to the invention, being potent inhibitors of the growth and proliferation of the P. falciparum parasite in human blood, are beneficial in the treatment of malaria.

[0004] Furthermore, the compounds according to the invention may be useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.Thus, the compounds of the invention may be useful as radioligands in assays for detecting pharmacologically active compounds.

[0005] WO 2019 / 192992, WO 2020 / 229427, WO 2021 / 032687 and WO 2022 / 008639 describe a particular class of heterocyclic compounds that are stated to be potent inhibitors of the growth and proliferation of the P. falciparum parasite in human blood and therefore beneficial in the treatment of malaria.

[0006] WO 2017 / 142825 describes a family of heterocyclic compounds that are stated to be potent inhibitors of P. falciparum growth in vitro that may be useful in the treatment of malaria.

[0007] WO 2017 / 089453 and WO 2017 / 144517 describe heterocyclic compounds that are stated to be potent and selective inhibitors of plasmepsin V activity that are useful for the treatment of malaria.

[0008] WO 2016 / 172255 describes a class of heterocyclic compounds that are stated to be BACE inhibitors that may be useful in the treatment of amyloid-β protein-associated (Aβ-associated) pathologies, including Alzheimer's disease.

[0009] WO 2008 / 103351, WO 2006 / 065277 and WO 2005 / 058311 describe families of heterocyclic compounds which are said to be aspartyl protease inhibitors. The compounds described in these publications are also said to be effective in methods for the treatment of malaria, particularly in inhibiting plasmepsins (particularly plasmepsins I and II).

[0010] WO 2006 / 041404 describes a family of heterocyclic compounds that are said to be inhibitors of beta-site APP (amyloid precursor protein) cleaving enzyme (BACE). The compounds described in that publication are also said to be effective in methods of modulating BACE activity and in methods of treating or preventing Aβ-related pathologies, including Down's syndrome and Alzheimer's disease. Summary of the Invention

[0011] The present invention provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof [ka] (In the formula, Z represents aryl or heteroaryl, either of which may be optionally substituted by one or more substituents; R 1 is C 3-7 Cycloalkyl, C 3-7 Cycloalkyl(C 1-6 ) Alkyl, aryl (C 1-6 ) Alkyl, C 3-7 Heterocycloalkyl, C 3-7 Heterocycloalkyl(C 1-6 ) Alkyl, C 4-9 Heterobicycloalkyl, C 4-9 Spiroheterocycloalkyl or heteroaryl (C 1-6 ) alkyl, any of which may be optionally substituted by one or more substituents; R 2 , R 3 and R 4 each independently represents hydrogen, halogen or trifluoromethyl.

[0012] The present invention also provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof as hereinbefore defined for use in therapy.

[0013] The present invention also provides a compound of formula (I) or a pharma- ceutically acceptable salt thereof as defined above for use in the treatment and / or prophylaxis of malaria.

[0014] The present invention also provides a method for treating and / or preventing malaria which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined above or a pharma- ceutically acceptable salt thereof.

[0015] The present invention also provides the use of a compound of formula (I) or a pharma- ceutically acceptable salt thereof as defined above, for the manufacture of a medicament for the treatment and / or prevention of malaria. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] Where any of the groups in the compounds of formula (I) above are described as optionally substituted, the group may be unsubstituted or substituted by one or more substituents. Typically, such groups are unsubstituted or substituted by 1, 2 or 3 substituents, typically 1 or 2 substituents.

[0017] When used in medicine, the salt of the compound of formula (I) is a pharmaceutically acceptable salt.However, other salts may be useful in the preparation of the compound or its pharmaceutically acceptable salt for use in the present invention.The standard principles underlying the selection and preparation of pharmaceutically acceptable salts are described, for example, in Handbook of Pharmaceutical Salts: Properties, Selection and Use, edited by P.H. Stahl & C.G. Wermuth, Wiley-VCH, 2002.

[0018] Suitable alkyl groups which may be present in the compounds used in the present invention include straight chain and branched C 1-6 Alkyl groups, such as C 1-4 alkyl groups. Typical examples include methyl and ethyl groups, as well as straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 2,2-dimethylpropyl and 3-methylbutyl. 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfonyl" and "C 1-6 Derived expressions such as "alkylamino" should be construed accordingly.

[0019] As used herein, "C 3-7 The term "cycloalkyl" refers to a monovalent radical of 3 to 7 carbon atoms derived from a saturated monocyclic hydrocarbon, and may include its benzo-fused analogues. 3-7Cycloalkyl groups include cyclopropyl, cyclobutyl, benzocyclobutenyl, cyclopentyl, indanyl, cyclohexyl, and cycloheptyl.

[0020] The term "aryl" as used herein refers to a monovalent carbocyclic aromatic group derived from a single aromatic ring or multiple fused aromatic rings. Suitable aryl groups include phenyl and naphthyl, preferably phenyl.

[0021] Preferred aryl (C 1-6 ) Alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl.

[0022] As used herein, "C 3-7 The term "heterocycloalkyl" refers to a saturated monocyclic ring containing from 3 to 7 carbon atoms and at least one heteroatom selected from oxygen, sulfur and nitrogen, and may include benzo-fused analogs thereof. Suitable heterocycloalkyl groups include oxetanyl, azetidinyl, tetrahydrofuranyl, dihydrobenzo-furanyl, dihydrobenzothienyl, pyrrolidinyl, indolinyl, isoindolinyl, oxazolidinyl, thiazolidinyl, isothiazolidinyl, imidazolidinyl, tetrahydropyranyl, chromanyl, dioxanyl, tetrahydrothiopyranyl, piperidinyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, piperazinyl, 1,2,3,4-tetrahydroquinoxalinyl, hexahydro-[1,2,5]thiadiazolo-[2,3-a]pyrazinyl, homopiperazinyl, morpholinyl, benzoxazinyl, thiomorpholinyl, azepanyl, oxazepanyl, diazepanyl, thiadiazepanyl, and azocanyl.

[0023] As used herein, "C 4-9The term "heterobicycloalkyl" refers to a monovalent radical of 4 to 9 carbon atoms derived from a saturated bicyclic hydrocarbon containing one or more heteroatoms selected from oxygen, sulfur, and nitrogen. Exemplary heterobicycloalkyl groups include 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 7-oxabicyclo[2.2.1]hexanyl, 6-azabicyclo[3.2.0]heptanyl, 3-azabicyclo[3.1.1]heptanyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[4.1.0]heptanyl, 2-oxabicyclo[2.2.2]-octanyl, quinuclidinyl, 2-oxa-5-azabicyclo[2.2.2]-octanyl, quinuclidin ... ]octanyl, 3-azabicyclo[3.2.1]octanyl, 8-oxabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]octanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,6-diazabicyclo[3.2.2]nonanyl, 3-oxa-7-azabicyclo-[3.3.1]nonanyl, 3,7-dioxa-9-azabicyclo[3.3.1]nonanyl and 3,9-diazabicyclo[4.2.1]nonanyl.

[0024] As used herein, "C 4-9The term "spiroheterocycloalkyl" refers to a saturated bicyclic ring system containing 4 to 9 carbon atoms and at least one heteroatom selected from oxygen, sulfur and nitrogen, where the two rings are joined by a common atom. Suitable spiroheterocycloalkyl groups include 5-azaspiro[2.3]hexanyl, 5-azaspiro[2.4]-heptanyl, 2-oxaspiro[3.3]heptanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-6-azaspiro[3.3]-heptanyl, 3-oxa-6-azaspiro[3.3]heptanyl, 6-thia-2-azaspiro[3.3]heptanyl, 2-oxa-6-aza-spiro[3.4]octanyl, 2-oxa-6-azaspiro[3.5]nonanyl, 7-oxa-2-azaspiro[3.5]nonanyl, 2-oxa-7-azaspiro[3.5]nonanyl, and 2,4,8-triazaspiro[4.5]decanyl.

[0025] The term "heteroaryl," as used herein, refers to a monovalent aromatic group containing at least five atoms derived from a single ring or multiple fused rings, in which one or more carbon atoms are replaced by one or more heteroatoms selected from oxygen, sulfur, and nitrogen. Suitable heteroaryl groups include furyl, benzofuryl, dibenzofuryl, thienyl, benzothienyl, thieno[2,3-c]pyrazolyl, thieno[3,2-c]pyridinyl, dibenzothienyl, pyrrolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrazolyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, pyrazolo[1,5-a]pyrimidinyl, indazolyl, 4,5,6,7-tetrahydroindazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzyl, Examples include midazolyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-a]-pyridinyl, imidazo[1,5-a]pyridinyl, pyridinyl[4,5-b]pyridinyl, purinyl, imidazo[1,2-a]-pyrimidinyl, imidazo[1,2-a]pyrazinyl, oxadiazolyl, thiadiazolyl, triazolyl, [1,2,4]triazolo-[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, benzotriazolyl, tetrazolyl, pyridinyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyridazinyl, cinnolinyl, phthalazinyl, pyrimidinyl, quinazolinyl, pyrazinyl, quinoxalinyl, pteridinyl, triazinyl and chromenyl.

[0026] As used herein, the term "halogen" is intended to include fluorine, chlorine, bromine and iodine atoms, typically fluorine, chlorine or bromine.

[0027] The absolute stereochemical configuration of the chiral carbon atoms in the imino-tetrahydropyrimidinone nucleus of the compounds according to the invention is as shown in formula (I) above. In general, the compounds according to the invention are at least 51% enantiomerically pure (meaning that the sample contains a mixture of enantiomers containing 51% or more of the enantiomer shown in formula (I) and 49% or less of the opposite antipode). Typically, the compounds according to the invention are at least 60% enantiomerically pure. Preferably, the compounds according to the invention are at least 75% enantiomerically pure. Preferably, the compounds according to the invention are at least 80% enantiomerically pure. More preferably, the compounds according to the invention are at least 85% enantiomerically pure. Even more preferably, the compounds according to the invention are at least 90% enantiomerically pure. Even more preferably, the compounds according to the invention are at least 95% enantiomerically pure. Preferably, the compounds according to the invention are at least 99% enantiomerically pure. Ideally, compounds according to the invention are at least 99.9% enantiomerically pure.

[0028] When the compounds of formula (I) have one or more additional asymmetric centers, they may exist as enantiomers accordingly. When the compounds according to the invention have one or more additional asymmetric centers, they may exist as diastereomers. It should be understood that the present invention extends to the use of all such enantiomers and diastereomers, and mixtures thereof in any proportion, including racemates. Formula (I) and the formulae shown below are intended to represent all individual stereoisomers and all possible mixtures thereof, unless otherwise stated or indicated. Furthermore, compounds of formula (I) may exist as tautomers, such as keto (CH2C=O) <-> enol (CH=CHOH) tautomers or amide (NHC=O) <-> hydroxyimine (N=COH) tautomers or imide (NHC=NH) <-> aminoimine (N=CNH2) tautomers. Formula (I) and the formulae shown below are intended to represent all individual tautomers and all possible mixtures thereof, unless otherwise stated or indicated. Furthermore, for example, R 2Under certain circumstances where represents a halogen, compounds of formula (I) may exist as atropisomers. Formula (I) and the formulae depicted below are intended to represent all individual atropisomers and all possible mixtures thereof, unless otherwise stated or indicated.

[0029] It is to be understood that each individual atom present in formula (I) or in any of the formulae shown below may in fact be present in the form of any of its naturally occurring isotopes, with the most abundant isotopes being preferred. Thus, by way of example, each individual hydrogen atom present in formula (I) or in any of the formulae shown below may be: 1 H, 2 H (deuterium; D) or 3 H (tritium; T) atoms, preferably 1 H. Similarly, by way of example, each individual carbon atom present in formula (I) or in the formulae shown below may be present as: 12 C. 13 C or 14 C atom, preferably 12 It may also exist as C.

[0030] In a first embodiment, Z represents aryl, which may be optionally substituted by one or more substituents. In a second embodiment, Z represents heteroaryl, which may be optionally substituted by one or more substituents.

[0031] Typically, Z is phenyl, naphthyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzothienyl, thieno[2,3-c]pyrazolyl, thieno[3,2-c]pyridinyl, dibenzothienyl, pyrrolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrazolyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[2,3-b]pyridinyl, pyrazolo ... pyrazolo[3,4-b]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, indazolyl, 4,5,6,7-tetrahydroindazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-a]pyridinyl aryl, imidazo[1,5-a]pyridinyl, imidazo[4,5-b]pyridinyl, purinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-a]pyrazinyl, oxadiazolyl, thiadiazolyl, triazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl , benzotriazolyl, tetrazolyl, tetrazolo[1,5-a]pyridinyl, pyridinyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyridazinyl, cinnolinyl, phthalazinyl, pyrimidinyl, quinazolinyl, pyrazinyl, quinoxalinyl, pteridinyl, triazinyl or chromenyl, any of which groups may be optionally substituted by one or more substituents.

[0032] Suitably, Z represents phenyl, naphthyl, pyrrolo[2,3-b]pyridinyl, pyrazolyl, pyrazolo[1,5-a]pyrimidinyl, indazolyl, isoxazolyl, benzimidazolyl, triazolyl, pyridinyl, pyridazinyl or pyrimidinyl, any of which groups may be optionally substituted by one or more substituents.

[0033] Suitably, Z represents phenyl or pyridinyl, either of which may be optionally substituted by one or more substituents.

[0034] Typical examples of optional substituents on Z include halogen, cyano, nitro, C 1-6 Alkyl, difluoromethyl, trifluoromethyl, trifluoroethyl, C 2-6 Alkenyl, C 2-6 Alkynyl, cyclopropyl, cyclobutyl, difluorocyclobutyl (C 1-6 ) alkyl, phenyl, fluorophenyl, trifluorophenyl, benzyl, phenyl-(C 2-6 ) alkenyl, morpholinyl, azepanyl, pyrrolidinyl (C 1-6 ) alkyl, 2-oxabicyclo[2.1.1]hexanyl-(C 1-6 ) alkyl, pyrazolyl, imidazolyl, (C 1-6 ) Alkyl imidazolyl, pyridinyl, pyridinyl (C 1-6 ) Alkyl, Hydroxy, Hydroxy(C 1-6 ) alkyl, (difluoro)(hydroxy)(C 1-6 ) alkyl, (trifluoro)(hydroxy)(C 1-6 )-Alkyl, oxo, C 1-6 Alkoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoroethoxy, C 1-6 Alkoxy(C 1-6 ) Alkyl, phenoxy, methylenedioxy, difluoromethylenedioxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) Alkyl-amino, Amino(C 1-6 ) alkyl, di(C 1-6 ) Alkylamino(C 1-6 ) Alkyl, C 2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C2-6 Alkylcarbonyl, Carboxy, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 ) alkylaminosulfonyl, di(C 1-6 ) alkyl-sulfoximino and di(C 1-6 ) alkylphosphoryl.

[0035] Suitable examples of optional substituents on Z include halogen, cyano, C 1-6 Alkyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, difluorocyclobutyl (C 1-6 ) alkyl, phenyl, fluoro-phenyl, trifluorophenyl, benzyl, phenyl (C 2-6 ) alkenyl, morpholinyl, azepanyl, pyrrolidinyl-(C 1-6 ) alkyl, 2-oxabicyclo[2.1.1]hexanyl (C 1-6 ) alkyl, pyrazolyl, pyridinyl, pyridinyl-(C 1-6 ) alkyl, (difluoro)(hydroxy)(C 1-6 ) alkyl, (trifluoro)(hydroxy)(C 1-6 ) Alkyl, oxo, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 Alkoxy(C 1-6 ) Alkyl, C 1-6 Alkylsulfonyl, di(C 1-6 ) Alkylamino(C 1-6 ) Alkyl, C 1-6 Alkyl sulfonyl amino, di(C 1-6 )Alkyl sulfoximino and di(C 1-6 ) alkylphosphoryl.

[0036] Suitable examples of optional substituents on Z include 1, 2 or 3 substituents independently selected from halogen.

[0037] Representative examples of specific substituents on Z include fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, difluoromethyl, trifluoromethyl, trifluoroethyl, vinyl, allyl, propynyl, cyclopropyl, cyclobutyl, difluorocyclobutylmethyl, phenyl, fluorophenyl, trifluorophenyl, benzyl, phenylethenyl, morpholinyl, azepanyl, pyrrolidinylethyl, 2-oxabicyclo[2.1.1]hexanylethyl, pyrazolyl, imidazolyl, methyl-imidazolyl, pyridinyl, pyridinylmethyl, pyridinylethyl, hydroxy, hydroxymethyl, hydroxyethyl, (difluoro)(hydroxy)ethyl, (trifluoro)(hydroxy)(hydroxy)ethyl, hydroxyisopropyl, aryl, aryloxy ... and 1, 2, or 3 substituents independently selected from xo, methoxy, isopropoxy, difluoromethoxy, difluoroethoxy, trifluoromethoxy, trifluoro-ethoxy, methoxymethyl, methoxyethyl, phenoxy, methylenedioxy, difluoromethylene-dioxy, methylthio, methylsulfinyl, methylsulfonyl, amino, methylamino, dimethylamino, aminomethyl, dimethylaminomethyl, dimethylaminoethyl, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl, dimethylaminosulfonyl, dimethylaminosulfonyl, and dimethylphosphoryl.

[0038] Suitable examples of specific substituents on Z include one, two or three substituents independently selected from fluoro, chloro, cyano, methyl, isopropyl, n-butyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, difluorocyclobutylmethyl, phenyl, fluorophenyl, trifluorophenyl, benzyl, phenylethenyl, morpholinyl, azepanyl, pyrrolidinylethyl, 2-oxabicyclo[2.1.1]hexanylethyl, pyrazolyl, pyridinyl, pyridinylmethyl, pyridinylethyl, (difluoro)(hydroxy)ethyl, (trifluoro)(hydroxy)ethyl, oxo, methoxy, difluoromethoxy, trifluoromethoxy, methoxyethyl, methylsulfonyl, dimethylaminoethyl, methylsulfonylamino, dimethylsulfoximino and dimethylphosphoryl.

[0039] Suitable examples of particular substituents on Z include 1, 2 or 3 substituents independently selected from fluoro and chloro.

[0040] Typical values ​​for Z include phenyl, fluorophenyl, chlorophenyl, cyanophenyl, methylphenyl, isopropylphenyl, tert-butylphenyl, trifluoromethylphenyl, propynylphenyl, morpholinylphenyl, pyrazolylphenyl, imidazolylphenyl, methylimidazolylphenyl, (difluoro)(hydroxy)ethylphenyl, (trifluoro)(hydroxy)ethylphenyl, methoxyphenyl, isopropoxyphenyl, difluoromethoxyphenyl, trifluoromethoxyphenyl, phenoxyphenyl, methylenedioxyphenyl, difluoromethylenedioxyphenyl, methylsulfonylphenyl, methylsulfonylaminophenyl, methoxycarbonylphenyl, dimethylsulfoxyiminophenyl, dimethylphosphorylphenyl, difluorophenyl, (chloro)(fluoro)phenyl, (cyano)(fluoro)-phenyl, (fluoro)(methyl)phenyl, (fluoro)(trifluoromethyl)phenyl, (fluoro)(methoxy)-phenyl, (fluoro)(difluoromethoxy)phenyl, (fluoro)(tri ... (fluoro)-(methylsulfonyl)phenyl, (dimethylsulfoximino)(fluoro)phenyl, (dimethylphosphoryl)(fluoro)phenyl, dichlorophenyl, (chloro)(cyano)phenyl, (chloro)(methyl)phenyl, (chloro)(difluoromethoxy)phenyl, (chloro)(trifluoromethoxy)phenyl, (chloro)(methylsulfonyl)-phenyl, (cyano)(trifluoromethyl)phenyl, (cyano)(methoxy)phenyl, (cyano)(difluoromethoxy)phenyl, dimethylphenyl, dimethoxyphenyl, (methyl toxo)(methylsulfonyl)phenyl, trifluorophenyl, (chloro)(difluoro)phenyl, naphthyl, methoxynaphthyl, cyanofuryl, fluorobenzofuryl, (cyano)(methyl)pyrrolyl, methylindolyl, methylpyrrolo[2,3-b]pyridinyl, pyrazolyl, methylpyrazolyl, trifluoroethylpyrazolyl, dimethylpyrazolyl, (methyl)(trifluoromethyl)pyrazolyl, (dimethyl)(phenyl)pyrazolyl, pyrazolo[1,5-a]pyridinyl, fluoropyrazolo[1,5-a]pyridinyl, methylpyrazolo[3,4-b]pyridinyl, pyrazolo[1,5-a]-pyrimidinyl, methylindazolyl, isoxazolyl, methylisoxazolyl, cyclopropylisoxazolyl, methylimidazolyl, trifluoroethylbenzimidazolyl, [1,2-a]pyridinyl, methylimidazo-[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, methylimidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyrazinyl, methyloxadiazolyl, butyltriazolyl, trifluoroethyltriazolyl, cyclobutyltriazolyl, difluorocyclobutylmethyltriazolyl triazolyl, phenyltriazolyl, fluorophenyltriazolyl, trifluorophenyltriazolyl, benzyltriazolyl, phenylethenyltriazolyl, azepanyltriazolyl, pyrrolidinylethyltriazolyl, 2-oxabicyclo[2.1.1]hexanylethyltriazolyl, pyridinyltriazolyl, pyridinylmethyltriazolyl, pyridinylethyltriazolyl, methoxyethyltriazolyl, dimethylaminoethyltriazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, tetrazolo[1,5-a]pyridinyl, pyridinyl, fluoropyridinyl, chloropyridinyl, cyanopyridinyl, methylpyridinyl, ethyl-pyridinyl, tert-butylpyridinyl, difluoromethylpyridinyl, trifluoromethylpyridinyl, trifluoroethylpyridinyl, propynylpyridinyl, cyclopropylpyridinyl, morpholinylpyridinyl, methoxypyridinyl, difluoromethoxypyridinyl, trifluoromethoxypyridinyl, difluoroethoxy-pyridinyl, trifluoroethoxypyridinyl, dimethylaminopyridinyl, difluoropyridinyl, (fluoro)-(trifluoromethyl)pyridinyl, (fluoro)(methoxy)pyridinyl, (chloro)(methyl)pyridinyl, (chloro)(trifluoromethyl)pyridinyl, (cyano)(methyl)pyridinyl, (cyano)(difluoromethyl)pyridinyl, (methyl)(trifluoromethyl)pyridinyl, (fluoromethyl)pyridinyl, (methyl)(oxo)pyridinyl, (methoxy)-(methyl)pyridinyl, (methoxy)(trifluoromethyl)pyridinyl, (difluoromethoxy)(methyl)-pyridinyl, quinolinyl, cyanoquinolinyl, difluoromethoxyquinolinyl, isoquinolinyl, methylisoquinolinyl, difluoromethoxyisoquinolinyl, naphthyridinyl, pyridazinyl, methylpyridazinyl, trifluoromethylpyridazinyl, trifluoroethoxypyridazinyl, cinnolinyl, pyrimidinyl, chloropyrimidinyl, methylpyrimidinyl, tert-butylpyrimidinyl, trifluoro-methylpyrimidinyl, pyrazinyl, methylpyrazinyl, tert-butylpyrazinyl, methoxypyrazinyl, difluoromethoxypyrazinyl, dimethylaminopyrazinyl, quinoxalinyl and trifluoromethyl-quinoxalinyl.

[0041] Suitable values ​​of Z include chlorophenyl, cyanophenyl, isopropylphenyl, trifluoromethylphenyl, morpholinylphenyl, pyrazolylphenyl, (difluoro)(hydroxy)ethyl-phenyl, (trifluoro)(hydroxy)ethylphenyl, methylsulfonylphenyl, methylsulfonylamino-phenyl, dimethylsulfoximinophenyl, dimethylphosphorylphenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methylsulfonyl)phenyl, (dimethylsulfoximino)(fluoro)-phenyl, (dimethylphosphoryl)(fluoro)phenyl, dichlorophenyl, (chloro)(trifluoromethoxy)-phenyl, naphthyl, methylpyrrolo[2,3-b]pyridinyl, pyrazolyl, trifluoroethylpyrazolyl, dimethylpyrazolyl, pyrazolo[1,5-a]pyrimidinyl, methylindazolyl, isoxazolyl, methyl-isoxazolyl, triazolyl, cyclopropylisoxazolyl, trifluoroethylbenzimidazolylbutyltriazolyl, trifluoro-ethyltriazolyl, cyclobutyltriazolyl, difluorocyclobutylmethyltriazolyl, phenyltriazolyl, fluorophenyltriazolyl, trifluorophenyltriazolyl, benzyltriazolyl, phenylethenyltriazolyl, azepanyltriazolyl, pyrrolidinylethyltriazolyl, 2-oxabicyclo[2.1.1]hexanylethyltriazolyl, pyridinyltriazolyl, pyridinylmethyltriazolyl, pyridinylethyltriazolyl, methoxyethyl-triazolyl, dimethylaminoethyltriazolyl, pyridinyl, chloropyridinyl, cyclopropylpyridinyl, methoxypyridinyl, difluoromethoxypyridinyl, trifluoromethoxypyridinyl, (methyl)(oxo)-pyridinyl, pyridazinyl and pyrimidinyl.

[0042] Typically, R 1 is C 3-7 Cycloalkyl, C 3-7 Cycloalkyl(C 1-6 ) Alkyl, aryl (C 1-6 ) Alkyl, C 3-7 Heterocycloalkyl, C3-7 Heterocycloalkyl(C 1-6 ) alkyl or heteroaryl (C 1-6 ) alkyl, any of which may be optionally substituted with one or more substituents.

[0043] Preferably, R 1 is C 3-7 Cycloalkyl, C 3-7 Cycloalkyl(C 1-6 ) alkyl or C 3-7 any of these groups may be optionally substituted with one or more substituents.

[0044] More specifically, R 1 is C 3-7 Cycloalkyl or C 3-7 and heterocycloalkyl, any of which may be optionally substituted with one or more substituents.

[0045] R 1 Representative examples include cyclobutyl, cyclohexyl, cyclopropylethyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, oxetanylmethyl, tetrahydropyranylmethyl, 7-oxabicyclo[2.2.1]heptanyl, 8-oxabicyclo[3.2.1]octanyl, and 2-oxaspiro[3.3]heptanyl, any of which may be optionally substituted by one or more substituents.

[0046] R 1 Suitable examples of include cyclobutyl, cyclohexyl, cyclopropylethyl, tetrahydropyranyl, tetrahydrothiopyranyl and piperidinyl, any of which groups may be optionally substituted with one or more substituents.

[0047] R 1Illustrative examples of include cyclohexyl and tetrahydropyranyl, either of which may be optionally substituted with one or more substituents.

[0048] R 1 Typical examples of the above optional substituents include halogen, cyano, nitro, C 1-6 Alkyl, difluoromethyl, trifluoromethyl, hydroxy, hydroxy(C 1-6 ) Alkyl, oxo, C 1-6 Alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di(C 1-6 ) Alkylamino, Amino(C 1-6 ) alkyl, di(C 1-6 ) Alkylamino(C 1-6 ) Alkyl, C 2-6 Alkylcarbonylamino, C 2-6 Alkoxycarbonylamino, C 1-6 Alkyl sulfonylamino, formyl, C 2-6 Alkylcarbonyl, Carboxy, C 2-6 Alkoxycarbonyl, aminocarbonyl, C 1-6 Alkylaminocarbonyl, di(C 1-6 ) Alkylaminocarbonyl, aminosulfonyl, C 1-6 Alkylaminosulfonyl and di(C 1-6 ) alkyl-aminosulfonyl.

[0049] R 1 Suitable examples of the above optional substituents include halogen, C 1-6 Alkyl, hydroxy, oxo, C 1-6 Alkoxy and di(C 1-6 ) alkylamino.

[0050] R1 Typical examples of the above specific substituents include 1, 2 or 3 substituents independently selected from fluoro, chloro, bromo, cyano, nitro, methyl, ethyl, isopropyl, difluoromethyl, trifluoromethyl, hydroxy, hydroxymethyl, hydroxyethyl, hydroxyisopropyl, oxo, methoxy, difluoromethoxy, trifluoromethoxy, methylthio, methylsulfinyl, methylsulfonyl, amino, methylamino, dimethylamino, aminomethyl, dimethylaminomethyl, acetylamino, methoxycarbonylamino, methylsulfonylamino, formyl, acetyl, carboxy, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methyl-aminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, methylaminosulfonyl and dimethylaminosulfonyl.

[0051] R 1 Suitable examples of the above specific substituents include 1, 2 or 3 substituents independently selected from fluoro, methyl, hydroxy, oxo, methoxy and dimethylamino.

[0052] R 1 Exemplary values ​​include dimethylaminocyclobutyl, (hydroxy)(methyl)-cyclohexyl, (difluoro)(methyl)cyclohexyl, (difluoro)(hydroxy)cyclohexyl, (difluoro)-(methoxy)cyclohexyl, hydroxycyclopropylethyl, methyltetrahydropyranyl, hydroxytetrahydropyranyl, (dioxo)(methyl)tetrahydrothiopyranyl, methylpiperidinyl and dimethylpiperidinyl.

[0053] R 1 Exemplary values ​​of include (difluoro)(methyl)cyclohexyl and (difluoro)-(methoxy)cyclohexyl.

[0054] In general, R 2 , R 3 and R 4 each independently represents hydrogen or halogen.

[0055] In general, R 2 represents hydrogen or halogen.

[0056] In the first embodiment, R 2 represents hydrogen. In a second embodiment, R 2 represents halogen, in particular fluoro or chloro. In one aspect of this embodiment, R 2 In another aspect of this embodiment, R 2 represents chloro. In a third embodiment, R 2 represents trifluoromethyl.

[0057] R 2 Selected values ​​of include hydrogen, fluoro and chloro.

[0058] Preferably, R 2 represents chloro.

[0059] In general, R 3 represents hydrogen or halogen, in particular hydrogen.

[0060] In the first embodiment, R 3 represents hydrogen. In a second embodiment, R 3 represents halogen, in particular fluoro or chloro. In one aspect of this embodiment, R 3 In another aspect of this embodiment, R 3 represents chloro. In a third embodiment, R 3 represents trifluoromethyl.

[0061] R 3 Selected values ​​of include hydrogen, fluoro and chloro.

[0062] Preferably, R 3 represents hydrogen or fluoro.

[0063] In general, R 4 represents hydrogen or halogen, in particular hydrogen.

[0064] In the first embodiment, R 4 represents hydrogen. In a second embodiment, R 4 represents halogen, in particular fluoro or chloro. In one aspect of this embodiment, R 4 In another aspect of this embodiment, R 4 represents chloro. In a third embodiment, R 4 represents trifluoromethyl.

[0065] Preferably, R 2 represents hydrogen or halogen, R 3 represents hydrogen or halogen, R 4 represents hydrogen.

[0066] Preferably, R 2 represents a halogen, and R 3 represents hydrogen or halogen, R 4 represents hydrogen.

[0067] In general, R 2 represents hydrogen or halogen, R 3 and R 4 Both represent hydrogen.

[0068] More specifically, R 2 represents a halogen, and R 3 and R 4 Both represent hydrogen.

[0069] One subclass of compounds according to the present invention is represented by the compounds of formula (IIA) and pharma- ceutically acceptable salts thereof: [ka] (In the formula, W is O, S(O)2, NR 12 , CH(OH) or CF2, R 11 represents hydrogen, methyl, hydroxy or methoxy; R 12 represents hydrogen or methyl; Z and R2 is as defined above).

[0070] In a first embodiment, W represents O. In a second embodiment, W represents S(O). In a third embodiment, W represents NR. 12 In a fourth embodiment, W represents CH(OH). In a fifth embodiment, W represents CF2.

[0071] Suitably, W represents O or CF2.

[0072] In the first embodiment, R 11 represents hydrogen. In a second embodiment, R 11 represents methyl. In a third embodiment, R 11 represents hydroxy. In a fourth embodiment, R 11 represents methoxy.

[0073] Preferably, R 11 represents methyl or methoxy.

[0074] In the first embodiment, R 12 represents hydrogen. In a second embodiment, R 12 represents methyl.

[0075] Specific novel compounds according to the invention include each of the compounds whose preparation is described in the accompanying examples, and their pharma- ceutically acceptable salts.

[0076] The present invention also provides pharmaceutical compositions comprising a compound according to the invention as described above, or a pharma- ceutically acceptable salt thereof, in association with one or more pharma- ceutically acceptable carriers.

[0077] Pharmaceutical compositions according to the invention may be in a form suitable for oral, buccal, parenteral, nasal, topical, ocular or rectal administration, or in a form suitable for administration by inhalation or insufflation.

[0078] For oral administration, the pharmaceutical compositions can take the form of tablets, lozenges or capsules prepared by conventional means with pharma- ceutically acceptable excipients, such as binders (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropylmethylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium glycolate); or wetting agents (e.g., sodium lauryl sulfate). Tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharma- ceutically acceptable excipients, such as suspending agents, emulsifying agents, non-aqueous vehicles or preservatives. The preparations can also contain buffer salts, flavoring agents, coloring agents or sweetening agents, as appropriate.

[0079] Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

[0080] For buccal administration, the compositions can take the form of tablets or lozenges formulated in conventional manner.

[0081] The compound of formula (I) can be formulated for parenteral administration by injection, for example, by bolus injection or infusion. The formulation for injection can be provided in unit dosage form, for example, in glass ampoules or in multi-dose containers, for example, glass vials. The composition for injection can take the form of a suspension, solution or emulsion in an oily or aqueous vehicle, and can contain formulating agents such as suspending agents, stabilizing agents, preservatives and / or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.

[0082] In addition to the formulations described above, the compounds of formula (I) can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation or intramuscular injection.

[0083] For administration intranasally or by inhalation, the compounds according to the invention can be conveniently delivered in the form of an aerosol spray for a pressurized pack or nebulizer using a suitable propellant, for example, dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

[0084] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispenser device may be accompanied by instructions for administration.

[0085] For topical administration, the compound used in the present invention can be conveniently formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more pharma- ceutically acceptable carriers.Specific carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water.Alternatively, the compound used in the present invention can be formulated into a suitable lotion containing the active ingredient suspended or dissolved in one or more pharma-ceutically acceptable carriers.Specific carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water.

[0086] For ocular administration, the compounds used in the present invention can be conveniently formulated as micronized suspensions in isotonic pH-adjusted sterile saline with or without preservatives, such as bactericides or fungicides, such as phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.Alternatively, for ocular administration, the compounds can be formulated in an ointment such as petrolatum.

[0087] For rectal administration, the compound used in the present invention can be conveniently formulated as suppositories.These can be prepared by mixing the active ingredient with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, and therefore melts in the rectum to release the active ingredient.Such materials include, for example, cocoa butter, beeswax and polyethylene glycol.

[0088] The amount of the compound used in the present invention required to prevent or treat a particular condition will vary depending on the compound selected and the condition of the patient being treated. In general, however, the daily dosage may range from about 10 ng / kg to 1000 mg / kg, typically 100 ng / kg to 100 mg / kg, e.g., about 0.01 mg / kg to 40 mg / kg body weight, for oral or buccal administration, about 10 ng / kg to 50 mg / kg body weight, for parenteral administration, and about 0.05 mg to about 1000 mg, e.g., about 0.5 mg to about 1000 mg, for intranasal administration or administration by inhalation or insufflation.

[0089] The compounds according to the invention can be prepared by reacting a boronic acid derivative of formula ZB(OH)2 or its cyclic ester formed with an organic diol, such as pinacol, 1,3-propanediol or neopentyl glycol, with a boronic acid derivative of formula (III): [ka] (In the formula, Z, R 1 , R 2 , R 3 and R 4 is as defined above, and L 1 represents a suitable leaving group, R p represents hydrogen or an N-protecting group), and then, if necessary, the N-protecting group R p The compound may be prepared by a method comprising removing

[0090] Leaving group L 1 preferably represents halogen, such as bromo or iodo.

[0091] Suitably, the transition metal catalyst used in the above process comprises [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II). Alternatively, the transition metal catalyst may comprise chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2) or (2-dicyclohexyl-phosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (XPhos Pd G3), either of which may be advantageously used in conjunction with 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos).

[0092] The reaction may generally be carried out in the presence of a base, for example an inorganic base such as sodium carbonate, potassium carbonate or cesium carbonate, or potassium phosphate. The reaction may be carried out at elevated temperature in water and a suitable organic solvent, for example a cyclic ether, for example 1,4-dioxane, or C 1-4 It is conveniently carried out in an alkanol, for example ethanol.

[0093] Preferably, the N-protecting group R p is tert-butoxycarbonyl (BOC).

[0094] N-protecting group R p When is BOC, subsequent removal of the BOC group may be conveniently accomplished by treatment with an acid, for example a mineral acid such as hydrochloric acid, or an organic acid such as trifluoroacetic acid. The reaction is typically carried out at ambient temperature in a suitable solvent, for example a chlorinated solvent such as dichloromethane, or a cyclic ether such as 1,4-dioxane.

[0095] L 1 The intermediate of formula (III) above, wherein represents iodine, can be converted into a compound of formula (IV): [ka] (In the formula, R 1 , R 2 , R 3 , R 4 and R p is as defined above) with copper(I) iodide in the presence of tert-butyl nitrite.

[0096] The reaction is conveniently effected in a suitable solvent, such as acetonitrile, at elevated temperature.

[0097] Alternatively, the intermediate of formula (III) above can be reacted with a compound of formula (V): [ka] (In the formula, R 1 , R 2 , R 3 , R 4 , L 1 and R p is as defined above, and R w is C 1-4 It may also be prepared by cyclization of an alkyl group.

[0098] Cyclization of compound (V) is conveniently carried out by treatment with a base.

[0099] Preferably, the base used in the cyclization reaction is 1-4 The alkoxide salt, typically an alkali metal alkoxide such as potassium tert-butoxide, The reaction is conveniently effected in a suitable solvent, for example a cyclic ether such as tetrahydrofuran, at ambient temperature.

[0100] The intermediate of formula (V) can be prepared by reacting a compound of formula (VI) with a compound of formula (VII): [ka] (In the formula, R 1 , R 2 , R 3 , R 4 , L1 , R p and R w is as defined above).

[0101] Generally, the reaction of compound (VI) with (VII) is carried out in the presence of a coupling agent. A suitable coupling agent is N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC.HCl). Preferably, the reaction is carried out in the presence of a base, typically an organic base such as N,N-diisopropylethylamine.

[0102] The reaction of compounds (VI) and (VII) is conveniently accomplished at ambient temperature in a suitable solvent, for example a dipolar aprotic solvent such as N,N-dimethylformamide.

[0103] Under certain circumstances, the reaction of compounds (VI) with (VII) proceeds directly to the corresponding compound of formula (III).

[0104] The intermediate of formula (VI) above is provided by incorporating an N-protecting group R t Removal of the compound of formula (VIII): [ka] (In the formula, R 2 , R 3 , R 4 , L 1 and R w is as defined above, and R t represents an N-protecting group).

[0105] Preferably, the N-protecting group R t is tert-butoxycarbonyl (BOC).

[0106] N-protecting group R t When is BOC, removal of the BOC group may conveniently be achieved by treatment with an acid, for example a mineral acid such as hydrochloric acid, or an organic acid such as trifluoroacetic acid.

[0107] L 1 The intermediate of formula (VIII), wherein represents iodine, can be converted into a compound of formula (IX): [ka] (In the formula, R 2 , R 3 , R 4 , R w and R t is as defined above), compound (IV) is converted to compound (III) (wherein L 1 represents iodine) by reaction with copper(I) iodide in the presence of tert-butyl nitrite.

[0108] The intermediate of formula (IX) above may be prepared by a process comprising the steps of: (i) N-protecting group R t with a compound of formula (X): [ka] (In the formula, R 2 , R 3 , R 4 and R w is as defined above, and R q represents an N-protecting group), and (ii) removing the N-protecting group R from the material thus obtained q A process of removing

[0109] N-protecting group R t When represents BOC, step (i) can be conveniently carried out by reacting compound (X) with di-tert-butyl dicarbonate. The reaction is generally carried out in the presence of a mild base, such as an alkali metal bicarbonate, for example sodium hydrogen carbonate. The reaction is conveniently carried out in water and an organic solvent, such as a cyclic ether, such as tetrahydrofuran, at ambient temperature.

[0110] Preferably, the N-protecting group Rq is benzyloxycarbonyl.

[0111] N-protecting group R q When represents benzyloxycarbonyl, removal of the benzyloxycarbonyl group in step (ii) may be conveniently achieved by catalytic hydrogenation. Typically, this involves treatment with gaseous hydrogen in the presence of a hydrogenation catalyst such as palladium on charcoal.

[0112] The intermediates of formula (IV) and (X) above may be prepared by methods similar to those described in WO 2021 / 032687.

[0113] In another procedure, the compound according to the invention can be prepared by reacting a compound of formula (XI): [ka] (In the formula, Z, R 1 , R 2 , R 3 , R 4 , R p and R w is as defined above) is cyclized under conditions similar to those described above for the cyclization of compound (V), and then, optionally, the N-protecting group R p The compound may be prepared by a method comprising removing

[0114] The intermediate of formula (XI) above can be prepared by reacting a compound of formula (VII) as defined above with a compound of formula (XII): [ka] (In the formula, Z, R 2 , R 3 , R 4 and R w is as defined above) under conditions similar to those described above for the reaction of compounds (VI) with (VII).

[0115] The intermediate of formula (XII) can be prepared by reacting a boronic acid derivative of formula ZB(OH)2 or a cyclic ester thereof formed by an organic diol, such as pinacol, 1,3-propanediol or neopentyl glycol, with a compound of formula (VIII) as defined above under conditions similar to those described above for the reaction of compound (III) with a boronic acid derivative of formula ZB(OH)2 or a cyclic ester thereof formed by an organic diol, followed by the removal of the N-protecting group R under conditions similar to those described above. t It may be prepared by removing

[0116] In another procedure, Z represents a 1,2,3-triazol-4-yl moiety substituted at the 1-position by a substituent Y, i.e. Z has the formula (Za): [ka] The compounds according to the invention, which represent a group of the formula (XIII), wherein the asterisk (*) represents the point of attachment to the rest of the molecule, can be prepared by reacting an azide derivative Y-N3 with a compound of the formula (XIII): [ka] (In the formula, R 1 , R 2 , R 3 , R 4 and R p is as defined above), followed, if necessary, by the reaction of the N-protecting group R p The compound may be prepared by a method comprising removing

[0117] The reaction of the azide derivative Y-N3 with compound (XIII) is suitably carried out in the presence of copper(II) sulfate and sodium ascorbate. The reaction is optionally carried out in an organic solvent, such as C 2 O, such as tert-butanol. 1-4 It may conveniently be carried out in water in the presence of an alkanol at ambient or elevated temperature.

[0118] The intermediate of formula (XIII) above may be prepared by a process comprising the steps of: (i) reacting a compound of formula (III) as defined above with trimethylsilyl-acetylene; and (ii) removing the trimethylsilyl groups from the material thereby obtained.

[0119] Step (i) is generally effected in the presence of a transition metal catalyst. Suitably, the transition metal catalyst comprises bis(triphenylphosphine)-palladium(II) dichloride. The reaction is generally effected in the presence of copper(I) iodide and a base, for example an organic amine such as triethylamine. The reaction is conveniently carried out in a suitable organic solvent, for example a cyclic ether such as tetrahydrofuran, at ambient temperature.

[0120] The removal of the trimethylsilyl group in step (ii) may be conveniently carried out by treatment with a base, for example an alkali metal carbonate, such as potassium bicarbonate. The reaction is carried out in a suitable organic solvent, for example C 2 O, such as methanol. 1-4 It is conveniently carried out in an alkanol at ambient temperature.

[0121] If they are not commercially available, starting materials of formula (VII) may be prepared by methods analogous to those described in the accompanying examples or by standard methods well known in the art.

[0122] It is understood that any compound of formula (I) initially obtained from any of the above methods can, if appropriate, then be elaborated to further compounds of formula (I) by techniques known in the art. For example, a compound containing an N-BOC moiety (BOC stands for tert-butoxy-carbonyl) can be converted to the corresponding compound containing an NH moiety by treatment with an acid, for example a mineral acid, for example hydrochloric acid, or an organic acid, for example trifluoroacetic acid.

[0123] Compounds containing a tert-butyldimethylsilyloxy moiety can be converted to the corresponding compounds containing a hydroxy moiety by treatment with tetra-n-butylammonium fluoride.

[0124] Compounds containing a formyl (-CHO) moiety can be converted to the corresponding compounds containing -CH(OH)CHF2 functional groups by treatment with (difluoromethyl)trimethylsilane in the presence of cesium fluoride followed by treatment with tetra-n-butylammonium fluoride. Similarly, compounds containing a formyl (-CHO) moiety can be converted to the corresponding compounds containing -CH(OH)CF3 functional groups by treatment with (trifluoromethyl)trimethylsilane in the presence of cesium fluoride followed by treatment with tetra-n-butylammonium fluoride.

[0125] Compounds containing an NH functionality can be converted to the corresponding compounds containing an N-CH3 functionality by treatment with formaldehyde in the presence of a reducing agent such as sodium cyanoborohydride.

[0126] When a mixture of products is obtained from any of the above-described processes for the preparation of compounds according to the invention, the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC or column chromatography, for example utilizing silica and / or alumina with a suitable solvent system.

[0127] If the above-mentioned method for preparing the compounds according to the invention results in a mixture of stereoisomers, these isomers can be separated by conventional techniques. In particular, if it is desired to obtain a particular enantiomer of a compound of formula (I), this may be produced from the corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers. Thus, for example, diastereomeric derivatives, for example salts, can be produced by reaction of a mixture of enantiomers, for example racemates, of formula (I) with a suitable chiral compound, for example a chiral base. The diastereomers can then be separated by any convenient means, for example by crystallization, and the desired enantiomer can be recovered, for example by treatment with an acid if the diastereomer is a salt. In another method of resolution, the racemate of formula (I) can be separated using chiral HPLC. Furthermore, if desired, a particular enantiomer can be obtained by using a suitable chiral intermediate in one of the above-mentioned methods. Alternatively, a specific enantiomer can be obtained by enantiospecific enzymatic biotransformation, such as ester hydrolysis using an esterase, followed by purification of only the enantiomerically pure hydrolyzed acid from the unreacted ester enantiomer. Chromatography, recrystallization and other conventional separation procedures can also be used with intermediates or final products when it is desired to obtain a specific geometric isomer of the invention.

[0128] During any of the above synthetic sequences, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved using conventional protecting groups such as those described in Greene's Protective Groups in Organic Synthesis, edited by PGM Wuts, John Wiley & Sons, 5th Edition, 2014. The protecting groups may be removed at any convenient subsequent stage using methods known in the art.

[0129] The following examples illustrate the preparation of compounds according to the invention.

[0130] The compounds of the present invention are potent inhibitors of the growth and proliferation of the Plasmodium falciparum parasite in human blood. Thus, they are active in the P. falciparum 3D7 asexual blood stage assay with IC values ​​of 50 μM or less, generally 20 μM or less, usually 5 μM or less, typically 1 μM or less, suitably 500 nM or less, ideally 100 nM or less, preferably 20 nM or less. 50 values ​​are shown (those skilled in the art may prefer 50 (Understand that the higher the value, the more active the compound).

[0131] Asexual blood-stage assay The assay used to measure the effect of test compounds on bloodstream stages of the 3D7 strain of Plasmodium falciparum uses SYBR Green as a readout, a dye that binds to double-stranded deoxyribonucleic acid (DNA) resulting in an increase in fluorescence, allowing the detection of P. falciparum DNA in infected red blood cells, thereby providing a measure of parasite growth and reproduction.

[0132] Maintenance of P. falciparum cultures Red blood cells (A+ blood) were prepared for both parasite culture and assay by washing four times with incomplete medium (15.9 g RPMI 1640 (25 mM HEPES, L-glutamine), 1 g NaHCO3, 2 g glucose, 400 μL gentamicin (500 mg / mL), 2 mL hypoxanthine solution (13.6 g / L in 0.1 M NaOH pH 7.3) in 1 liter medium). After centrifugation at 1800 g for 5 min, the supernatant was decanted and resuspended in fresh incomplete medium. At the last wash, the cells were resuspended in complete medium (incomplete medium with 5 g / L Albumax II) and centrifuged at 1800 g for 3 min. This cell sediment was treated as 100% hematocrit.

[0133] P. falciparum 3D7 was cultured in red blood cells at a hematocrit of 5% in complete medium at 37°C (1% O2, 3% CO2, balance N2). Cultures were split weekly to achieve a parasitemia of 1% in red blood cells at a hematocrit of 5% in fresh medium. Culture medium is replaced with fresh medium every other day (twice a week).

[0134] Assay procedure On day 1, test compounds were added to the assay plate using Echo dispensing technology (1.5-fold dilutions and 20-point titrations). 50 nL of each compound dilution was added to 50 μL of culture (5% hematocrit, 0.5% parasitemia) and incubated for 72 h at 37 °C (1% O2, 3% CO2, balance N2). Final concentrations of test compounds ranged from 50,000 nM to 15 nM in 0.5% DMSO.

[0135] On day 4, 10 μL of SYBR Green (Invitrogen S7563 supplied as a 10,000x concentrate in DMSO) prediluted to a 3x concentrate in Lysis buffer (20 mM Tris pH 7.9, 5% EDTA, 0.16% w / v, 1.6% TX100 v / v) was added to the cultures and incubated overnight at room temperature in the dark.

[0136] Fluorescence signal was measured on day 5 using a BioTek plate reader (excitation 485 nm, emission 528 nm). All data were processed using IDBS ActivityBase. Raw data were converted to percent inhibition by linear regression by setting the high inhibition control (mefloquine) to 100% and the no inhibition control (DMSO) to 0%. Quality control criteria for passing plates were as follows: Z'>0.5, S:B>3, %CV (阻害なし対照) <15. The formula used to calculate Z' is:

number

[0137] All E.C. 50 Curve fitting was performed using XLfit model 300 (IDBS) using the following biphasic two-site dose response:

number

[0138] When tested in the P. falciparum 3D7 asexual blood stage assay described above, the compounds of the accompanying examples exhibited the following IC 50 It was found to exhibit value. [Table 1-1] [Table 1-2]

[0139] example Abbreviation DCM: dichloromethane EtOAc: ethyl acetate DMSO: Dimethyl sulfoxide THF: Tetrahydrofuran MeOH: Methanol DMF: N,N-Dimethylformamide DIPEA: N,N-diisopropylethylamine TFA: trifluoroacetic acid TFAA: Trifluoroacetic anhydride EtOH: Ethanol DME: 1,2-dimethoxyethane DMAP: 4-(dimethylamino)pyridine DAST: (Diethylamino) sulfur trifluoride TBAF: Tetra-n-butylammonium fluoride EDC.HCl: N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene XPhos: 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl XPhos Pd G2: Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) XPhos Pd G3: (2-dicyclohexylphosphino 2',4',6'-triisopropyl-1,1'-biphenyl) [2-(2'-amino-1,1'-biphenyl)] palladium(II) methanesulfonate Pd2(dba)3: Tris(dibenzylideneacetone)dipalladium(0) Pd(dppf)Cl2: [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) h: time M: mass rt room temperature RT: retention time DAD: Diode array detector HPLC: High-performance liquid chromatography UPLC: Ultra-high performance liquid chromatography LCMS: Liquid Chromatography Mass Spectrometry ESI: electrospray ionization

[0140] nomenclature Compounds were named according to IUPAC guidelines using Biovia Draw version 20.1.

[0141] For example, an asterisk (*) in a compound designated (2R*,4R*) indicates a compound of known relative stereochemistry but unknown absolute stereochemistry.

[0142] Analysis conditions Method 1 Stationary phase: Waters X Bridge C18, 2.1×30mm, 2.5μm Injection volume: 5.0 μL Flow rate: 1.00mL / min Detection: MS-ESI+m / z 150~800 UV-DAD 220~400nm Mobile phase A: 5 mM ammonium formate aqueous solution + 0.1% ammonia Mobile phase B: Acetonitrile + 5% Mobile phase A + 0.1% Ammonia Gradient program: 5% B to 95% B in 4.0 min; hold until 5.00 min; 5. At 10 min, the concentration of B is 5%; 6. Hold until 5 min

[0143] Method 2 Stationary phase: Phenomenex Gemini NX-C18 2×20mm, 3μM Mobile phase A: 10 mM ammonium formate aqueous solution + 0.1% ammonia solution Mobile phase B: acetonitrile + 5% water + 0.1% ammonia solution Flow rate: 1mL / min Gradient Program: Time A% B% 0.00 95.00 5.00 4.00 5.00 95.00 5.00 5.00 95.00 5.10 95.00 5.00

[0144] Method 3 Stationary phase: Phenomenex Gemini NX-C18 2×20mm, 3μm Mobile phase A: 10 mM ammonium formate aqueous solution + 0.1% ammonia solution Mobile phase B: acetonitrile + 5% water + 0.1% ammonia solution Flow rate: 1mL / min Gradient Program: Time A% B% 0.00 95.00 5.00 4.00 5.00 95.00 5.00 5.00 95.00 5.10 95.00 5.00

[0145] Method 4 Stationary phase: Waters Acquity UPLC BEH C18 2.1×50mm, 1.7μm Mobile phase A: 10 mM ammonium formate aqueous solution + 0.1% ammonia solution Mobile phase B: acetonitrile + 5% water + 0.1% ammonia solution Flow rate: 1.5mL / min Gradient Program: Time A% B% 0.00 95.00 5.00 0.10 95.00 5.00 3.50 5.00 95.00 4.00 5.00 95.00 4.05 95.00 5.00

[0146] Method 5 Stationary phase: Waters Acquity UPLC BEH C18 2.1×50mm, 1.7μm Mobile phase A: Water / acetonitrile / ammonium formate (95:5:63mg / L) + 100μg / L NH4OH Mobile phase B: Acetonitrile / water / ammonium formate (95:5:63mg / L) + 100μg / L NH4OH Flow rate: 0.8mL / min Gradient Program: Time A% B% 0.00 99.00 1.00 0.15 99.00 1.00 1.60 5.00 95.00 1.65 5.00 95.00 2.00 5.00 95.00 2.05 99.00 1.00 2.75 99.00 1.00

[0147] Method 6 Stationary phase: Waters UPLC X Bridge BEH (C18, 2.1×50mm, 2.5μm) Temperature: 45℃ Injection volume: 1.0μL Flow rate: 1.00mL / min Detection: Mass spectrometry - + / - detection in the same run PDA: 210~400nm Mobile phase A: 10 mM ammonium formate aqueous solution + 0.1% formic acid Mobile phase B: 95% acetonitrile + 5% H2O + 0.1% formic acid Gradient Program: Time %A %B 0 95 5 5 0.10 95 5 2.10 5 95 2.35 5 95 2.80 95 5

[0148] Method 7 LC-MS analyses were performed on a Quattro micro API Tandem Quadrupole System Waters mass spectrometer equipped with a Waters 2720 LC separation module using an X-bridge C18 3.5 μm column in fundamental mode (water / acetonitrile / ammonium formate) and a Waters 996 (210–400 nm) photodiode array detector.

[0149] Intermediate 1 tert-Butyl (NE)-N-{(4S)-4-(2-chloro-3-iodophenyl)-4-methyl-1-[(2S,4S)-2-methyl-tetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene}carbamate To a suspension of tert-butyl (NE)-N-{(4S)-4-(3-amino-2-chlorophenyl)-4-methyl-1-[(2S,4S)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene}-carbamate (WO 2022 / 008639, intermediate 9) (10.0 g, 22.2 mmol) in acetonitrile (60 mL) was added tert-butyl nitrite (90% by weight) (4.4 mL, 33.0 mmol) at 0° C., followed by CuI (8.50 g, 45.0 mmol). The reaction mixture was stirred at 60° C. for 5 h and filtered. The filtrate was quenched with saturated aqueous NH4Cl / NH4OH (2:1, ca. 100 mL) and extracted with EtOAc (100 mL). The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-30% EtOAc in DCM) to give the title compound (UV purity 85%) (6.8 g, 46%) as a fluffy white powder. LCMS (Method 2, ESI): 561.8 [MH] + , RT 2.97 minutes.

[0150] Intermediate 2 6-Bromo-1-(2,2,2-trifluoroethyl)benzimidazole To a solution of 6-bromo-1H-benzimidazole (700 mg, 3.45 mmol) in THF (15 mL) was added NaH (60% by weight in mineral oil) (210 mg, 5.25 mmol) at room temperature. After 5 min, 2,2,2-trifluoroethyl trifluoromethanesulfonate (1.8 mL) was added. The reaction mixture was stirred at room temperature for 2 h, then carefully quenched with water (5 mL) and diluted with DCM (10 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 30% EtOAc in hexanes) to give the title compound (50% by weight; 1:1 mixture with regioisomeric 5-bromo-1-(2,2,2-trifluoroethyl)benzimidazole) (905 mg, 94%) as a yellow solid. LCMS (Method 3, ESI): 281.0 [MH] + , RT 0.95 min.

[0151] Intermediate 3 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2 trifluoroethyl)benzimidazole A suspension of intermediate 2 (50% by weight) (905 mg, 3.24 mmol), potassium acetate (1.26 g, 12.8 mmol), bis(pinacolato)diboron (2.20 g, 8.2 mmol) and bis(triphenyl-phosphine)palladium(II) dichloride (450 mg, 0.64 mmol) in 1,4-dioxane (10 mL) was stirred at 90° C. for 3 h. The reaction mixture was quenched with water (20 mL) and diluted with EtOAc (50 mL). The phases were separated and the aqueous phase was washed with EtOAc (3×10 mL). The combined organic fractions were dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (silica, 40% EtOAc in hexanes) to give the title compound (45% by weight; 1:1 mixture with regioisomer 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)benzimidazole) (1.10 g, 97%) as a brown solid. LCMS (Method 3, ESI): 327.2 [MH] + , RT 1.08 minutes.

[0152] Intermediates 4 and 5 tert-Butyl N-[rac-(1S,3S,4R)-4-hydroxy-3-methylcyclohexyl]carbamate (Intermediate 4) tert-Butyl N-[rac-(1S,3S,4S)-4-hydroxy-3-methylcyclohexyl]carbamate (Intermediate 5) To a solution of tert-butyl N-(4-hydroxy-3-methylphenyl)carbamate (2.0 g, 8.96 mmol) in 2-propanol (40 mL) was added ruthenium supported on alumina (5% metal loading) (452.7 mg, 0.22 mmol). The mixture was placed in a stainless steel reactor under H2 atmosphere (10 bar) at 120 °C for 110 h and then cooled to room temperature. The mixture was filtered through a pad of diatomaceous earth and washed with 2-propanol. The solvent was removed in vacuo and the crude material was purified by flash chromatography (silica, 10-90% EtOAc in heptane) to give intermediate 4 (235 mg, 11%). The other fractions were combined, concentrated and repurified by flash chromatography (silica, 50% EtOAc in heptane with 0.1% diethylamine) to give intermediate 5 (150 mg, 7%). Intermediate 4: δ H (400 MHz,CDCl3)4.41(s,1H),3.75(q,J 2.7 Hz,1H),3.45(s,1H),1.88(dq,J 13.8,3.3 Hz,1H),1.80-1.49(m,4H),1.44(m,11H),1.21(q,J 11.8 Hz,1H),0.97(d,J 6.8 Hz,3H).LCMS(Method 7):230[MH] + , RT 5.24 minutes. Intermediate 5: δ H (400 MHz,CDCl3)4.34(s,1H),3.47(s,1H),3.12(td,J 10.4,4.1 Hz,1H),1.99(m,J 16.2,7.1,3.4 Hz,4H),1.77-1.30(m,11H),1.29-1.06(m,1H),1.02(d,J 6.5 Hz,3H),0.88(q,J 12.2 Hz,1H).LCMS(Method 7):230[MH] + , RT 5.10 minutes.

[0153] Intermediate 6 rac-(1R,2S,4S)-4-Amino-2-methylcyclohexanol hydrochloride Intermediate 4 (500.0 mg, 2.18 mmol) was dissolved in 1,4-dioxane (5 mL) and then 4N HCl in 1,4-dioxane (5 mL, 20 mmol) was added at room temperature. The mixture was stirred for 7 h and then concentrated in vacuo. The crude material was lyophilized to give the title compound (474 ​​mg, 2.86 mmol) as a clear oil which was used without further purification. δ H (300 MHz,DMSO-d6)7.99(s,3H),3.65-3.44(m,2H),2.95(d,J 4.9 Hz,1H),1.74(m,1H),1.68-1.18(m,6H),0.88(d,J 6.2 Hz,3H).

[0154] Intermediate 7 tert-Butyl N-{[rac-(1R,3R,4S)-4-hydroxy-3-methylcyclohexyl]carbamothioyl}carbamate Prepared from intermediate 6 (474.0 mg, 2.86 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 2 thereof) to give the title compound (460.0 mg, 56%) as an off-white solid. LCMS (Method 3, ESI): 287.2 [MH] - , RT 1.70 minutes.

[0155] Intermediate 8 tert-Butyl N-({rac-(1R,3R,4S)-4-[tert-butyl(dimethyl)silyl]oxy-3-methylcyclohexyl}-carbamothioyl)carbamate To a solution of intermediate 7 in DMF (3 mL) was added imidazole (548 mg, 8.0 mmol) and tert-butyldimethylchlorosilane (371.0 mg, 2.4 mmol) at 0° C. The mixture was stirred at room temperature for 20 h, then additional tert-butyldimethylchlorosilane (371 mg, 2.39 mmol) was added. The mixture was stirred at 40° C. for 3 h, then quenched with water (50 mL) and extracted with EtOAc (2×50 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-20% EtOAc in hexanes) to give the title compound (450 mg, 70%) as a colorless oil. LCMS (Method 3, ESI): 403.2 [MH] + , RT 3.81 minutes.

[0156] Intermediate 9 tert-Butyl (NE)-N-[(4S)-4-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-1-{(1SR,3SR,4RS)-4-[tert-butyl(dimethyl)silyl]oxy-3-methylcyclohexyl}-4-methyl-6-oxo-hexahydropyrimidin-2-ylidene]carbamate Prepared from intermediate 8 (450.0 mg, 1.12 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 8 therein) to give the title compound (500 mg, 62%) as an off-white solid. LCMS (Method 3, ESI): 713.2 [MH] + , RT 4.08 minutes.

[0157] Intermediate 10 tert-Butyl (NE)-N-[(4S)-4-(3-amino-2-chlorophenyl)-1-{(1SR,3SR,4RS)-4-[tert-butyl-(dimethyl)silyl]oxy-3-methylcyclohexyl}-4-methyl-6-oxohexahydropyrimidin-2-ylidene]carbamate Prepared from intermediate 9 (500 mg, 0.70 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 9 therein) to give the title compound (430 mg, 100%). LCMS (Method 3, ESI): 579.2 [MH] + , RT 3.74 minutes.

[0158] Intermediate 11 tert-Butyl (NE)-N-[(4S)-1-{(1SR,3SR,4RS)-4-[tert-butyl(dimethyl)silyl]oxy-3-methyl-cyclohexyl}-4-(2-chloro-3-iodophenyl)-4-methyl-6-oxohexahydropyrimidin-2-ylidene]carbamate Prepared from Intermediate 10 (430.0 mg, 0.74 mmol) following the procedure described for Intermediate 1 to give the title compound (180.0 mg, 31%) as a colorless oil. LCMS (Method 3, ESI): 690.2 [MH] + , RT 4.17 minutes.

[0159] Intermediate 12 (8-oxo-1,4-dioxaspiro[4.5]decan-7-yl)acetate A mixture of 1,4-dioxaspiro[4.5]decan-8-one (7.50 g, 48.0 mmol) and lead(IV) acetate (31.9 g, 72.0 mmol) in toluene (150 mL) was heated at 110° C. for 16 h, after which the reaction mixture was cooled to room temperature. It was filtered through a pad of Celite® and washed with EtOAc (3×150 mL). The organic layer was separated, then dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 20% EtOAc in hexanes) to give the title compound (6.56 g, 64%) as an off-white solid. δ H (400 MHz, DMSO-d6) 5.24 (dd, J 13.2, 6.8 Hz, 1H), 3.89-4.08 (m, 4H), 2.54-2.69 (m, 1H), 2.23-2.33 (m, 2H), 2.07 (s, 3H), 1.93-2.01 (m, 2H). One proton signal was merged with the solvent peak.

[0160] Intermediate 13 (8,8-Difluoro-1,4-dioxaspiro[4.5]decan-7-yl)acetate To a solution of intermediate 12 (13.5 g, 63.0 mmol) in dry DCM (270 mL) was added DAST (20.8 mL, 158 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 30 min and then heated at 50° C. for 5 h, after which the reaction mixture was quenched with saturated aqueous NaHCO3 (450 mL) and extracted with DCM (3×400 mL). The organic layer was separated and then dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 15% EtOAc in hexanes) to give the title compound (9.51 g, 64%) as a colorless oil. δ H (400 MHz,DMSO-d6)5.18-5.30(m,1H),3.85-3.99(m,4H),2.10-2.25(m,1H),2.08(s,3H),1.98-2.06(m,2H),1.87-1.98(m,1H),1.72-1.81(m,2H).

[0161] Intermediate 14 4,4-Difluoro-3-hydroxycyclohexanone To a solution of intermediate 13 (9.50 g, 40.2 mmol) in THF (95 mL) was added 10% aqueous HCl (380 mL) slowly at room temperature. The reaction mixture was stirred at room temperature for 16 h, then quenched with saturated aqueous NaHCO3 (450 mL) and extracted with DCM (3 x 450 mL). The organic layer was separated, washed with saturated aqueous NH4Cl (200 mL) and brine (200 mL), then dried over anhydrous Na2SO4 and concentrated in vacuo to give the crude title compound (4.50 g) as a colorless oil, which was used without further purification. δ H (400 MHz, CDCl3)4.22-4.33(m,1H),3.74(br s,1H),2.77-2.88(m,1H),2.45-2.68(m,4H),2.18-2.32(m,1H).

[0162] Intermediate 15 3-[tert-Butyl(dimethyl)silyl]oxy-4,4-difluorocyclohexanone To a solution of intermediate 14 (4.50 g, 30.0 mmol) in dry DCM (90 mL) was added imidazole (5.10 g, 74.9 mmol). The reaction mixture was cooled to 0° C. and then tert-butyldimethylsilyl chloride (11.3 g, 74.9 mmol) was added. The reaction mixture was stirred at room temperature for 16 h, then quenched with 10% aqueous NH4Cl (150 mL) and extracted with EtOAc (3×150 mL). The organic layer was separated and then dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 30% EtOAc in hexane) to give the title compound (7.00 g, 88%) as a colorless oil. δ H (400 MHz, CDCl3)4.18-4.27(m,1H),2.80(d,J 14.6 Hz,1H),2.34-2.60(m,4H),2.08-2.28(m,1H),0.89(s,9H),0.11(s,6H).

[0163] Intermediate 16 rac-(1R,3R)-N-benzyl-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluorocyclohexanamine To a solution of intermediate 15 (7.00 g, 26.5 mmol) in isopropanol (70 mL) under nitrogen atmosphere was added benzylamine (4.34 mL, 39.7 mmol) and acetic acid (0.50 mL). The reaction mixture was stirred at room temperature for 8 h, then NaBH4 (2.50 g, 39.7 mmol) was added. The reaction mixture was stirred at room temperature for 16 h, then quenched with cold water (500 mL) and extracted with EtOAc (3 x 150 mL). The organic layer was separated, then dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 30% EtOAc in hexanes) to give the title compound (8.00 g, 71%) as a pale yellow oil. δ H (400 MHz, CDCl3)7.32-7.44(m,5H),3.87(s,2H),3.74-3.83(m,1H),2.76-2.86(m,2H),2.08-2.25(m, 2H),1.98-2.07(m,1H),1.61-1.96(m,3H),0.88(s,9H),0.09(s,6H).LCMS(Method 1, ESI):356.10[MH] + , RT 2.57 minutes.

[0164] Intermediate 17 rac-(1R,5R)-5-(benzylamino)-2,2-difluorocyclohexanol To a solution of intermediate 16 (4.00 g, 9.39 mmol) in THF (60 mL) was added TBAF (1 M in THF, 14.1 mL) under nitrogen atmosphere at 0° C. The reaction mixture was stirred at room temperature for 2 h, then quenched with water (200 mL) and extracted with EtOAc (3×300 mL). The organic layer was separated, then dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by Combiflash chromatography (40% EtOAc in hexanes) to give the title compound (1.90 g, 84%) as a colorless oil. δ H(400 MHz, DMSO-d6) 1.22-1.44(m, 2H), 1.59-1.85(m, 2H), 1.88-2.07(m, 2H), 7.30(q, J 7.66 Hz, 4H), 7.13-7.24(m, 1H), 5.48-5.62(m, 1H), 3.69(s, 2H), 3.53-3.66(m, 1H), 2.53-2.66(m, 1H). Not a single exchangeable proton signal was observed in the NMR spectrum.

[0165] Intermediate 18 tert-Butyl N-benzyl-N-[rac-(1R,3R)-4,4-difluoro-3-hydroxycyclohexyl]carbamate To a solution of intermediate 17 (1.90 g, 7.87 mmol) in DCM (20 mL) was added triethylamine (2.20 mL, 15.7 mmol). The reaction mixture was stirred at room temperature for 15 min, then di-tert-butyl dicarbonate (2.06 g, 9.45 mmol) was added at 0° C. The reaction mixture was stirred at room temperature for 16 h, then diluted with DCM (150 mL) and washed with water (100 mL). The organic layer was separated, then dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by Combiflash chromatography (20% EtOAc in hexanes) to give the title compound (1.80 g, 67%) as an off-white solid. δ H (400 MHz,DMSO-d6)7.28-7.37(m,2H),7.17-7.27(m,3H),5.37(d,J 5.38 Hz,1H),4.34(s,2H),3.92 4.07(m,1H),3.55-3.75(m,1H),1.89-2.02(m,1H),1.40-1.84(m,5H),1.34(s,9H).LCMS(Method 1, ESI):286.00[MH] + , RT 2.11 minutes.

[0166] Intermediate 19 tert-Butyl N-benzyl-N-[rac-(1R,3R)-4,4-difluoro-3-methoxycyclohexyl]carbamate To a solution of intermediate 18 (1.50 g, 4.38 mmol) in THF (30 mL) was added NaH (0.26 g, 6.57 mmol) at 0° C. under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 30 min, then iodomethane (0.93 g, 6.57 mmol) was added. The reaction mixture was stirred at room temperature for 2 h, then poured into water (160 mL) and extracted with EtOAc (2×160 mL). The organic layer was separated, then dried over anhydrous Na2SO4 and concentrated in vacuo to give the crude title compound (1.72 g) as a pale yellow semi-solid, which was used without further purification. δ H (400 MHz, CDCl3)7.13-7.37(m,5H),4.20-4.50(m,3H),3.50(s,3H),3.25-3.45(m ,1H),2.02-2.19(m,2H),1.64-1.80(m,3H),1.40(s,9H),0.80-0.96(m,1H).

[0167] Intermediate 20 rac-(1R,3R)-N-benzyl-4,4-difluoro-3-methoxycyclohexanamine To a solution of intermediate 19 (1.70 g, 4.78 mmol) in DCM (20 mL) was added TFA (1.10 mL, 14.3 mmol) at 0° C. The reaction mixture was stirred at room temperature for 2 h, then poured into cold saturated aqueous NaHCO3 (80 mL) and extracted with EtOAc (3×80 mL). The organic layer was separated, then dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by Combiflash chromatography (40% EtOAc in hexanes) to give the title compound (1.10 g, 90%) as a colorless oil. δ H (400 MHz,DMSO-d6)7.25-7.38(m,4H),7.16-7.24(m,1H),3.71(s,2H),3.40-3.53(m,1H),3.37(s,3H),2.55-2. 63(m,1H),2.10-2.26(m,2H),1.92-2.05(m,1H),1.82-1.92(m,1H),1.60-1.80(m,1H),1.10-1.26(m,2H).

[0168] Intermediate 21 rac-(1R,3R)-4,4-difluoro-3-methoxy-cyclohexanamine To a solution of intermediate 20 (1.10 g, 4.31 mmol) in MeOH (22 mL) under nitrogen atmosphere was added 20% Pd / C (0.23 g, 0.43 mmol). The reaction mixture was stirred at room temperature under hydrogen pressure for 2 h, then filtered through a pad of Celite® and washed with MeOH (3×30 mL). The filtrate was concentrated in vacuo to give the title compound (0.67 g, 94%) as a colorless oil, which was used without further purification. δ H (400 MHz, DMSO-d6) 3.40-3.53 (m, 1H), 2.73 (t, J 10.76 Hz, 1H), 1.88-2.08 (m, 2H), 1.64-1.85 (m, 2H), 1.07-1.26 (m, 2H). Three proton signals fused to the solvent peaks and two exchangeable proton signals not observed in the NMR spectrum.

[0169] Intermediate 22 tert-Butyl N-{[rac-(1R,3R)-4,4-difluoro-3-methoxycyclohexyl]carbamothioyl}carbamate To a solution of N,N'-bis-tert-butoxycarbonylthiourea (1.09 g, 3.94 mmol) in THF (8 mL) was added NaH (0.47 g, 11.8 mmol) at 0°C. The reaction mixture was stirred at 0°C for 1 h, then TFAA (0.83 mL, 5.90 mmol) was added at 0°C. The reaction mixture was stirred at 0°C for 1 h, then a solution of intermediate 21 (0.65 g, 3.94 mmol) in THF (2 mL) was added at 0°C. The reaction mixture was stirred at room temperature for 16 h, then diluted with water (70 mL) and extracted with EtOAc (2 x 70 mL). The organic layer was separated and washed with brine (70 mL), then dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 100-200 mesh, 20% EtOAc in hexanes) to give the title compound (1.10 g, 85%) as a pale yellow solid. H(400 MHz,DMSO-d6)10.58(s,1H),10.20(d,J 6.85 Hz,1H),4.40-4.52(m,1H),3.59-3.70(m,1H),3.40(s,3H),1.70-2.15(m,6H),1.44(s,9H).LCMS(Method 1, ESI):325.10[MH] + , RT 1.98 minutes.

[0170] Intermediate 23 Methyl (3S)-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl)-3-({(Z)-N'-tert-butoxy-carbonyl-N-[rac-(1R,3R)-4,4-difluoro-3-methoxycyclohexyl]carbamimidoyl}amino)-butanoate To a solution of intermediate 22 (1.10 g, 3.36 mmol) and methyl (3S)-3-amino-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl]butanoate (WO 2022 / 008639, intermediate 7) (1.39 g, 3.36 mmol) in DMF (10 mL) was added EDC.HCl (0.96 g, 5.03 mmol) and DIPEA (1.17 mL, 6.71 mmol) at 0° C. The reaction mixture was stirred at room temperature for 16 h, then quenched with water (140 mL) and extracted with EtOAc (3×70 mL). The organic layer was separated, then dried over anhydrous Na2SO4 and concentrated in vacuo to give the crude title compound (2.80 g) as a pale yellow solid, which was used without further purification. LCMS (Method 1, ESI): 667.10 [MH] + , RT 2.35 minutes.

[0171] Intermediate 24 tert-Butyl (NE)-N-{(4S)-4-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-1-[(1RS,3RS)-4,4-difluoro-3-methoxycyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}-carbamate To a solution of intermediate 23 (2.80 g, 3.08 mmol) in dry THF (28 mL) was added potassium tert-butoxide (1 M in THF, 3.08 mL) at 0° C. The reaction mixture was stirred at 0° C. for 1.5 h, then quenched with water (150 mL) and extracted with EtOAc (3×80 mL). The organic layer was separated, then dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by Combiflash chromatography (25% EtOAc in hexanes) to give the title compound (1.88 g, 94%) as an off-white solid. δ H(400 MHz,DMSO-d6)10.51(d,J 2.45 Hz,1H),9.24(s,1H),7.58(d,J 7.82 Hz,1H),7.29-7.45(m,6H),7.18(d,J 4.40 Hz,1H),5.14(s,2H),4.45-4.63(m,1H),3.59(d,J 16.63 Hz,1H),3.36-3.53(m,1H),3.26-3.35(s,3H),2.16-2.43(m,2H),1.83-2.05(m,2H),1.76(s,3H), 1.56-1.70(m,1H),1.45(s,9H),1.26-1.35(m,1H),0.95-1.07(m,1H).LCMS(Method 1, ESI):635.05[MH] + , RT 2.36 minutes.

[0172] Intermediate 25 tert-Butyl (NE)-N-{(4S)-4-(3-amino-2-chlorophenyl)-1-[(1RS,3RS)-4,4-difluoro-3-methoxycyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate To a solution of intermediate 24 (1.88 g, 2.88 mmol) in MeOH (30 mL) was added 20% Pd / C (0.23 g, 0.43 mmol) under argon atmosphere. The reaction mixture was stirred at room temperature under hydrogen pressure for 45 min, then filtered through a pad of Celite® and washed with MeOH (4×40 mL). The filtrate was dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue was purified by Combiflash chromatography (20% EtOAc in hexanes) to give the title compound (1.21 g, 79%) as an off-white solid. δ H (400 MHz,DMSO-d6)10.46(s,1H),6.95-7.08(m,1H),6.75-6.83(m,1H),6.40-6.50(m, 1H),5.52(s,2H),4.49-4.67(m,1H),3.44-3.60(m,2H),3.28-3.36(s,3H),3.05- 3.16(m,1H),2.18-2.42(m,2H),1.84-2.07(m,1H),1.74-1.84(m,1H),1.73(s,3H) ),1.45(s,9H),1.21-1.31(m,1H),0.81-0.91(m,1H).LCMS(Method 1, ESI):500.95[MH] + , RT 2.06 minutes.

[0173] Intermediate 26 tert-Butyl (NE)-N-{(4S)-4-(2-chloro-3-iodophenyl)-1-[(1RS,3RS)-4,4-difluoro-3-methoxycyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from intermediate 25 (411 mg, 1.41 mmol) following the procedure described for intermediate 1 to give the title compound (UV purity 55%) (777 mg, 65%) as a white solid. LCMS (Method 4, ESI): 612.2 [MH] + , RT 2.38 minutes.

[0174] Intermediate 27 [(4-bromo-3-fluorophenyl)imino](dimethyl)(oxo)-λ 6 -Sulfan A nitrogen purged suspension of 1-bromo-2-fluoro-4-iodobenzene (1.05 g, 3.38 mmol), (dimethanesulfinylidene)amine (320 mg, 3.43 mmol), Cs2CO3 (3.15 g, 9.66 mmol), Xantphos (0.2 g, 0.34 mmol) and Pd2(dba)3 (0.15 g, 0.16 mmol) in 1,4-dioxane (4 mL) was stirred at 100 °C. The reaction mixture was quenched with water (10 mL) and DCM (20 mL). The phases were separated and the aqueous phase was washed with DCM (4 x 5 mL). The combined organic fractions were concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-100% MeOH in DCM) to give the title compound (0.88 g, 98%) as a dark brown solid. δ H (300 MHz,CDCl3)7.32(t,J 8.3 Hz,1H),6.85(dd,J 10.5,2.4 Hz,1H),6.74(ddd,J 8.6,2.5,0.9 Hz,1H),3.13(s,6H).LCMS(Method 2, ESI):267.8[MH] + , RT 1.50 min.

[0175] Intermediate 28 {[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]imino}(dimethyl)-(oxo)-lambda 6 -Sulfan Prepared from intermediate 27 (0.88 g, 3.31 mmol) following the procedure described for intermediate 3 to afford the title compound (80% by mass) (1.1 g, 85%) as a dark solid. δ H (300 MHz,CDCl3)7.58(dd,J 8.0,7.2 Hz,1H),6.83(dd,J 8.0,1.9 Hz,1H),6.74(dd,J 11.3,1.9 Hz,1H),3.16(s,6H),1.33(s,12H).LCMS(Method 3, ESI):314.2[MH] + , RT 1.44 minutes.

[0176] Intermediate 29 1-Bromo-2-fluoro-4-(methylsulfonyl)benzene To a solution of DL-proline (0.11 g, 0.97 mmol) in DMSO (4 mL) was added NaH (60% by weight in mineral oil) (39 mg, 0.975 mmol) and the mixture was stirred at room temperature for 5 min. CuI (185 mg, 0.97 mmol), sodium methanesulfinate (1.32 g, 12.9 mmol) and 1-bromo-2-fluoro-4-iodobenzene (1 g, 3.22 mmol) were added. The resulting suspension was stirred at 100 °C for 3 h and then quenched with water (10 mL) and DCM (20 mL). The phases were separated and the aqueous phase was washed with DCM (4 x 5 mL). The combined organic fractions were concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-50% EtOAc in hexanes) to give the title compound (75% by weight) (0.49 g, 45%) as a pale yellow crystalline solid. LCMS (Method 2, ESI): 271.6[M+H2O] + , RT 1.43 minutes.

[0177] Intermediate 30 2-[2-Fluoro-4-(methylsulfonyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Prepared from intermediate 29 (75% by weight) (0.49 g, 1.66 mmol) following the procedure described for intermediate 3 to afford the title compound (50% by weight) (0.92 g, 90%) as a viscous dark oil. H(300 MHz,CDCl3)7.82(dd,J 7.8,5.5 Hz,1H),7.58(dd,J 7.8,1.6 Hz,1H),7.47(dd,J 8.2,1.6 Hz,1H),2.94(s,3H),1.24(s,12H).LCMS(Method 3, ESI):318.2[M+H2O] + , RT 0.39 min.

[0178] Intermediate 31 tert-Butyl (NE)-N-{(4S)-4-(2-chloro-3-iodophenyl)-1-[(1S,3S)-4,4-difluoro-3-methyl-cyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from tert-butyl (NE)-N-{(4S)-4-(3-amino-2-chlorophenyl)-1-[(1S,3S)-4,4-difluoro-3-methylcyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}-carbamate (WO 2022 / 008639, Intermediate 42) (4.0 g, 8.2 mmol) following the procedure described for Intermediate 1 to give the title compound (2.1 g, 41%) as an off-white solid. LCMS (Method 5, ESI): 596.2 [MH]+, RT 1.92 min.

[0179] Intermediate 32 1-Bromo-4-(dimethylphosphoryl)-2-fluorobenzene A nitrogen purged suspension of 1-bromo-2-fluoro-4-iodobenzene (1.05 g, 3.38 mmol), dimethyl-phosphine oxide (320 mg, 3.43 mmol), Cs2CO3 (3150 mg, 9.66 mmol), xantphos (0.2 g, 0.34 mmol) and Pd2(dba)3 (0.15 g, 0.16 mmol) in 1,4-dioxane (4 mL) was stirred at 100 °C. The reaction mixture was quenched with water (10 mL) and DCM (20 mL). The phases were separated and the aqueous phase was washed with DCM (4 x 5 mL). The combined organic fractions were concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-100% MeOH in DCM) to give the title compound (0.87 g, 90%) as a yellow crystalline solid. δ H(300 MHz,CDCl3)7.58(ddd,J 8.1,6.5,3.0 Hz,1H),7.43(ddd,J 12.0,8.3,1.7 Hz,1H),7.29(ddd,J 11.0,8.0,1.7 Hz,1H),1.70(s,3H),1.66(s,3H).LCMS(Method 2, ESI):253.8[MH] + , RT 1.08 minutes.

[0180] Intermediate 33 2-[4-(Dimethylphosphoryl)-2-fluorophenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Prepared from intermediate 32 (0.87 g, 3.31 mmol) following the procedure described for intermediate 3 to afford the title compound (50% by mass) (0.96 g, 46%) as a dark viscous oil. H (300 MHz,CDCl3)7.71(ddd,J 7.5,5.5,3.8 Hz,1H),7.38-7.18(m,2H),1.62(s,3H),1.58(s,3H),1.19(s,12H).LCMS(Method 3, ESI):299.2[MH] + , RT 0.40 min.

[0181] Intermediate 34 rac-(1R,3R)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluorocyclohexanamine To a solution of intermediate 16 (1.9 g, 4.95 mmol) in MeOH (20 mL) at room temperature was added 10% Pd / C (0.26 g, 0.25 mmol). The reaction mixture was stirred under H2 at room temperature for 3 h, then filtered through a Celite pad and washed with MeOH (3 x 30 mL). The filtrate was concentrated in vacuo to give the crude title compound (1.20 g) as a colorless oil, which was used without further purification. δ H (400 MHz,DMSO-d6)3.78-3.95(m,1H),2.70-2.80(m,1H),1.51-2.04(m,6H),1.09-1.38(m,2H),0.86(s,9H),0.05(s,6H).

[0182] Intermediate 35 tert-Butyl N-({rac-(1R,3R)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluorocyclohexyl}-carbamothioyl)carbamate Prepared from intermediate 34 (1.00 g, 3.77 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 2 thereof) to give the title compound (1.51 g, 71%) as a light brown liquid. LCMS (Method 1, ESI): 368.95 [(M-tBu)+H] + , RT 2.63 minutes.

[0183] Intermediates 36 and 37 tert-Butyl (NE)-N-[(4S)-4-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-1-{(1S*,3S*)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluorocyclohexyl}-4-methyl-6-oxohexahydro-pyrimidin-2-ylidene]carbamate (Intermediate 36) tert-Butyl (NE)-N-[(4S)-4-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-1-{(1R*,3R*)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluorocyclohexyl}-4-methyl-6-oxohexahydro-pyrimidin-2-ylidene]carbamate (Intermediate 37) Prepared from intermediate 35 (1.25 g, 2.20 mmol) and methyl (3S)-3-amino-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl]butanoate (WO 2022 / 008639, intermediate 7) (0.91 g, 2.20 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 8 thereof) and purified by flash chromatography to give the title compounds (intermediate 36, 0.52 g, 39%, and intermediate 37, 0.53 g, 40%) as an off-white solid. Intermediate 36: δ H (400 MHz,DMSO-d6)10.47(s,1H),9.24(s,1H),7.59(d,J 7.83 Hz,1H),7.37-7.43(m,4H),7.27-7.36(m,2H),7.16(d,J 8.31 Hz,1H),5.14(s,2H),4.56(t,J 12.23 Hz,1H),3.78-3.93(m,1H),3.58(d,J 16.63 Hz,1H),3.12-3.26(m,1H),2.38-2.48(m,1H),2.19-2.36(m,1H),1.82-1.94(m,1H),1.75(s,3H),1.5 4-1.68(m,2H),1.44(s,9H),0.98-1.08(m,1H),0.84(s,9H),0.04(s,6H).LCMS(Method 1, ESI):735.35[MH] + , RT 2.74 minutes. Intermediate 37: δ H(400 MHz,DMSO-d6)10.50(s,1H),9.23(s,1H),7.58(d,J 8.31 Hz,1H),7.37-7.43(m,4H),7.26-7.36(m,2H),7.16(d,J 7.83 Hz,1H),5.14(s,2H),4.38-4.51(m,1H),3.71-3.88(m,1H),3.50-3.63(m,1H),3.14-3.24(m,1H),2.24-2.41(m,2H),1.87-1.97(m, 1H),1.73-1.78(m,3H),1.54-1.71(m,2H),1.44(s,9H),1.00-1.12(m,1H),0.79(s,9H),-0.03(s,6H).LCMS(Method 1, ESI):735.25[MH] + , RT 2.70 minutes.

[0184] Intermediate 38 tert-Butyl (NE)-N-[(4S)-4-(3-amino-2-chlorophenyl)-1-{(1S*,3S*)-3-[tert-butyl-(dimethyl)silyl]oxy-4,4-difluorocyclohexyl}-4-methyl-6-oxohexahydropyrimidin-2-ylidene]carbamate Prepared from intermediate 36 (0.50 g, 0.65 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 9 thereof) to give the title compound (0.32 g, 77%) as an off-white solid. δ H (400 MHz,DMSO-d6)10.42(s,1H),6.92-7.04(m,1H),6.78(d,J 7.82 Hz,1H),6.46(d,J 7.83 Hz,1H),5.53(br s,2H),4.58(t,J 11.74 Hz,1H),3.78-3.94(m,1H),3.44-3.57(m,1H),3.06-3.17(m,1H),2.37-2.48(m,1H),2.21-2.37(m,1H),1.82-1.96(m,1H),1.76-1.8 1(m,1H),1.72(s,3H),1.56-1.66(m,1H),1.44(s,9H),1.04-1.13(m,1H),0.84(s,9H),0.04(s,6H).LCMS(Method 1, ESI):601.15[MH]+,RT 2.58 minutes.

[0185] Intermediate 39 tert-Butyl (NE)-N-[(4S)-1-{(1S*,3S*)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluoro-cyclohexyl}-4-(2-chloro-3-iodophenyl)-4-methyl-6-oxohexahydropyrimidin-2-ylidene]-carbamate Prepared from intermediate 38 (0.35 g, 0.56 mmol) following the procedure described for intermediate 1 to give the title compound (0.23 g, 48%) as an off-white solid. LCMS (Method 1, ESI): 711.85 [MH] + , RT 1.96 minutes.

[0186] Intermediate 40 tert-Butyl (NE)-N-[(4S)-4-(3-amino-2-chlorophenyl)-1-{(1R*,3R*)-3-[tert-butyl-(dimethyl)silyl]oxy-4,4-difluorocyclohexyl}-4-methyl-6-oxohexahydropyrimidin-2-ylidene]carbamate Prepared from intermediate 37 (0.50 g, 0.65 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 9 thereof) to give the title compound (0.33 g, 80%) as an off-white solid. δ H (400 MHz,DMSO-d6)10.46(s,1H),6.88-7.00(m,1H),6.77(d,J 7.82 Hz,1H),6.46(d,J 7.34 Hz,1H),5.52(s,2H),4.39-4.54(m,1H),3.84(dd,J 15.41,4.16 Hz,1H),3.50(d,J 16.63 Hz,1H),3.06-3.18(m,1H),2.26-2.40(m,2H),1.88-1.97(m,1H),1.75-1.84(m,1H),1.73(s,3H),1.48 -1.53(m,1H),1.45(s,9H),1.05-1.16(m,1H),0.81(s,9H),-0.01(s,6H).LCMS(Method 1, ESI):601.10[MH] + , RT 2.54 minutes.

[0187] Intermediate 41 tert-Butyl (NE)-N-[(4S)-1-{(1R*,3R*)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluoro-cyclohexyl}-4-(2-chloro-3-iodophenyl)-4-methyl-6-oxohexahydropyrimidin-2-ylidene]-carbamate Prepared from intermediate 40 (1.7 g, 2.77 mmol) following the procedure described for intermediate 1 to afford the title compound (1.10 g, 49%) as an off-white solid. H(400 MHz,DMSO-d6)10.49(s,1H),7.96(d,J 7.82 Hz,1H),7.29-7.43(m,1H),7.00-7.12(m,1H),4.34-4.50(m,1H),3.75-3.94(m,1H),3.58(d,J 17.12 Hz,1H),3.15-3.23(m,1H),2.20-2.41(m,2H),1.86-1.97(m,1H),1.75-1.83(m,1H),1.73(s,3H),1.59 -1.67(m,1H),1.45(s,9H),0.93-1.01(m,1H),0.80(s,9H),-0.02(s,6H).LCMS(Method 1, ESI):712.05[MH] + , RT 2.71 minutes.

[0188] Intermediate 42 tert-Butyl (NE)-N-[(4S)-1-{(1R*,3R*)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluoro-cyclohexyl}-4-[2-chloro-3-(3-chlorophenyl)phenyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene]carbamate To a solution of intermediate 41 (0.62 g, 0.87 mmol) in 1,4-dioxane (20 mL) and water (5 mL) was added (3-chlorophenyl)boronic acid (0.14 g, 0.87 mmol), K3PO4 (0.55 g, 2.61 mmol) and Pd(dppf)Cl2 (0.06 g, 0.09 mmol). The reaction mixture was purged with argon for 10 min, heated at 80 °C for 2 h, then concentrated in vacuo. The residue was diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-25% EtOAc in hexanes) to give the title compound (0.59 g, 86%) as an off-white solid. LCMS (Method 1, ESI): 696.30 [MH] + , RT 2.91 minutes.

[0189] Intermediate 43 tert-Butyl (NE)-N-{(4S)-4-[2-chloro-3-(3-chlorophenylphenyl]-1-[(1R*,3R*)-4,4-difluoro-3-hydroxycyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate To a solution of intermediate 42 (0.58 g, 0.83 mmol) in THF (15 mL) was added 1M TBAF (0.83 mL, 0.83 mmol) at 0° C. over 10 min. The reaction mixture was stirred at room temperature for 1.5 h and then concentrated in vacuo. The residue was diluted with water (30 mL) and extracted with EtOAc (3×30 mL). The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-40% EtOAc in hexanes) to give the title compound (0.42 g, 86%) as an off-white solid. LCMS (Method 1, ESI): 582.15 [MH] + , RT 2.51 minutes.

[0190] Intermediate 44 tert-Butyl (NE)-N-{(4S)-1-[(1R*,3S*)-3-benzyloxy-4,4-difluorocyclohexyl]-4-[2-chloro-3-(3-chlorophenyl)phenyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate To a solution of intermediate 43 (110 mg, 0.18 mmol) in toluene (10 mL) was added (cyanomethylene)tributylphosphorane (130 mg, 0.54 mmol), followed by phenyl-methanol (20.0 mg, 0.22 mmol). The reaction mixture was heated at 60° C. for 12 h and then concentrated in vacuo. The crude residue was purified by preparative HPLC to give the title compound (35.0 mg, 29%) as an off-white solid. LCMS (Method 1, ESI): 671.88 [MH] + , RT 1.88 minutes.

[0191] Intermediate 45 tert-Butyl (NE)-N-{(4S)-4-[2-chloro-3-(3-chlorophenyl)phenyl]-1-[(1R*,3S*)-4,4-difluoro-3-hydroxycyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate To a solution of intermediate 44 (30.0 mg, 0.05 mmol) in MeOH (5 mL) was added 10% Pd / C (80 mg) at 0° C. The reaction mixture was stirred at room temperature under H2 atmosphere for 2 h, then filtered through a Celite pad and washed with MeOH (2×20 mL). The filtrate was concentrated in vacuo to give the crude title compound (24.0 mg) as a colorless liquid. LCMS (Method 1, ESI): 584.10 [MH] + , RT 2.31 minutes.

[0192] Intermediate 46 tert-Butyl (NE)-N-{(4S)-4-[2-chloro-3-(3-formylphenyl)phenyl]-4-methyl-1-[(2S,4S)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene}carbamate To a suspension of intermediate 1 (1.0 g, 1.53 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) were added 3-formylphenylboronic acid (685 mg, 4.57 mmol) and Cs2CO3 (2 g, 6.13 mmol) at room temperature. The reaction mixture was purged with argon for 10 min, then Pd(dppf)Cl2 (225 mg, 0.29 mmol) was added at room temperature. The reaction mixture was purged with nitrogen for 5 min and heated at 60 °C in a sealed tube for 1.5 h, then quenched with water (10 mL) and DCM (25 mL). The phases were separated and the aqueous phase was washed with DCM (4 x 5 mL). The combined organic fractions were concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-100% EtOAc in hexanes) to give the title compound (0.68 g, 83%) as a pale yellow solid. δ H (300 MHz,DMSO-d6)10.53(d,J 1.5 Hz,1H),10.08(s,1H),7.97(td,J 4.4,1.6 Hz,1H),7.89(q,J 1.4 Hz,1H),7.77-7.67(m,2H),7.57-7.35(m,3H),4.80-4.60(m,1H),3.79(dd,J 11.6,4.4 Hz,1H),3.70-3.54(m,1H),3.28-3.19(m,2H),2.37-2.22(m,1H),2.11(q,J 11.9 Hz,1H),1.84(s,3H),1.45(s,9H),1.36-0.96(m,5H),0.91-0.75(m,1H).LCMS(Method 3, ESI):540.2[MH] + , RT 2.70 minutes.

[0193] Intermediate 47 tert-Butyl (NE)-N-[(4S)-4-(2-chloro-3-{3-[(1SR)-2,2-difluoro-1-hydroxyethyl]phenyl}-phenyl)-4-methyl-1-[(2S,4S)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene]carbamate To a suspension of intermediate 46 (0.23 g, 0.43 mmol) in THF (3 mL) and DMF (1 mL) were added cesium fluoride (200 mg, 1.32 mmol) and (difluoromethyl)trimethylsilane (0.2 mL, 1 mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 h and then at 60 °C for 20 h, quenched with saturated aqueous NaHCO3 (10 mL) and diluted with EtOAc (10 mL). The phases were separated and the aqueous phase was washed with EtOAc (2 x 10 mL). The combined organic fractions were concentrated in vacuo. The crude residue was treated with a solution of TBAF (1 M in THF) (3 mL, 3 mmol) for 30 min, then the crude mixture was concentrated in vacuo. The residue was purified by flash chromatography (silica, 0-80% EtOAc in hexanes) to give the title compound (0.22 g, 88%) as a pale yellow solid. LCMS (Method 3, ESI): 592.2[MH] + , RT 2.56 minutes.

[0194] Intermediates 48 and 49 tert-Butyl (NE)-N-[(4S)-4-{2-chloro-3-[3-(1R*)(2,2-difluoro-1-hydroxyethyl)phenyl]-phenyl}-4-methyl-1-[(2S,4S)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene]carbamate (Intermediate 48) tert-Butyl (NE)-N-[(4S)-4-{2-chloro-3-[3-(1S*)(2,2-difluoro-1-hydroxyethyl)phenyl]-phenyl}-4-methyl-1-[(2S,4S)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene]carbamate (Intermediate 49) Intermediate 47 was subjected to chiral preparative HPLC (Column: Chiralpak IC 250×20 mm, 5 μm; Method: isocratic 10% MeOH (no additives) for 12 min; Temperature: 40° C.; Flow rate: 100 mL / min; ABPR: 60 bar) to give intermediate 48 (29 mg, 25%) and intermediate 49 (29 mg, 25%). Intermediate 48: SFC chiral LCMS peak 1, RT 5.44 min (dr=99:1). Intermediate 49: SFC chiral LCMS peak 2, RT 6.13 min (dr=10:90). SFC Chiral LCMS Conditions:- Column: Chiralpak IC 150 x 4.6 mm, 3 μm; Temperature: 35°C; Flow rate: 3 mL / min; Method: Isocratic 10% MeOH (no additives) over 10 min.

[0195] Intermediate 50 tert-Butyl (NE)-N-[(4S)-4-(2-chloro-3-{3-[(1SR)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-phenyl)-4-methyl-1-[(2S,4S)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene]carbamate To a suspension of intermediate 46 (0.23 g, 0.43 mmol) in THF (3 mL) and DMF (1 mL) were added cesium fluoride (200 mg, 1.32 mmol) and (trifluoromethyl)trimethylsilane (98% by weight) (0.2 mL, 1 mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 h, then quenched with saturated aqueous NaHCO3 (10 mL) and diluted with EtOAc (10 mL). The phases were separated and the aqueous phase was washed with EtOAc (2 x 10 mL). The combined organic fractions were concentrated in vacuo. The crude residue was treated with a solution of TBAF (1 M in THF) (3 mL, 3 mmol) for 30 min, then the crude mixture was concentrated in vacuo. The residue was purified by flash chromatography (silica, 0-80% EtOAc in hexanes) to give the title compound (0.27 g, 90%) as a pale yellow solid. LCMS (Method 3, ESI): 608.2[MH] + , RT 1.36 minutes.

[0196] Intermediates 51 and 52 tert-Butyl (NE)-N-[(4S)-4-{2-chloro-3-[3-(1R*)(2,2,2-trifluoro-1-hydroxyethyl)phenyl]-phenyl}-4-methyl-1-[(2S,4S)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene]carbamate (Intermediate 51) tert-Butyl (NE)-N-[(4S)-4-{2-chloro-3-[3-(1S*)-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]-phenyl}-4-methyl-1-[(2S,4S)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene]carbamate (Intermediate 52) Intermediate 50 was subjected to chiral preparative HPLC (Column: Chiralpak IC 250×20 mm, 5 μm; Method: isocratic 10% MeOH (no additives) for 12 min; Temperature: 40° C.; Flow rate: 100 mL / min; ABPR: 60 bar) to give intermediate 51 (20 mg, 15%) and intermediate 52 (20 mg, 15%). Intermediate 51: SFC chiral LCMS peak 1, RT 3.16 min (dr=97:3). Intermediate 52: SFC chiral LCMS peak 2, RT 3.48 min (dr=7:93). SFC Chiral LCMS Conditions:- Column: Chiralpak IC 150 x 4.6 mm, 3 μm; Temperature: 35°C; Flow rate: 3 mL / min; Method: Isocratic 10% MeOH (no additives) over 6.5 min.

[0197] Intermediate 53 Methyl (3S)-3-[3-(benzyloxycarbonylamino)-2-chlorophenyl]-3-(tert-butoxycarbonyl-amino)butanoate To a solution of methyl (3S)-3-amino-3-[3-(benzyloxycarbonylamino)-2-chloro-phenyl]butanoate (WO 2022 / 008639, intermediate 7) (7.1 g, 17.2 mmol) in THF (20 mL) was added di-tert-butyl dicarbonate (4.3 g, 19.7 mmol), sodium bicarbonate (4.4 g, 52.1 mmol) and water (3 mL) at room temperature. The reaction mixture was stirred at room temperature for 16 h, then quenched with water (50 mL) and extracted with EtOAc (3 x 50 mL). The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-50% EtOAc in hexanes) to give the title compound (7.02 g, 82%) as a colorless liquid. δ H (300 MHz,CDCl3)8.16(dd,J 8.1,1.6 Hz,1H),7.33-7.50(m,5H),7.28(dd,J 8.1,8.1 Hz,2H),7.17(dd,J 8.1,1.6 Hz,1H),5.81(s,1H),5.24(s,2H),3.68(s,3H),3.42(d,J 14.1 Hz,1H),2.80(d,J 14.1 Hz,1H),1.91(s,3H),1.36(s,9H).LCMS(Method 2, ESI):475.2[MH] + , RT 2.40 minutes.

[0198] Intermediate 54 Methyl (3S)-3-(3-amino-2-chlorophenyl)-3-(tert-butoxycarbonylamino)butanoate Prepared from intermediate 53 (2.7 g, 5.6 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 9 thereof) to give the title compound (2.0 g, 99%) as a colorless oil. δ H (300 MHz,CDCl3)7.09(dd,J 7.9,7.9 Hz,1H),6.81-6.96(m,2H),5.79(s,1H),3.72(s,2H),3.69(s,3H),3.47(d,J 14.1 Hz,1H),2.83(d,J 14.1 Hz,1H),1.91(s,3H),1.37(s,9H).LCMS(Method 3, ESI):243.2[MH-BOC] +, RT 1.03 minutes.

[0199] Intermediate 55 Methyl (3S)-3-(tert-butoxycarbonylamino)-3-(2-chloro-3-iodophenyl)butanoate Prepared from intermediate 54 (3.2 g, 8.9 mmol) following the procedure described for intermediate 1 to give the title compound (89% by mass) (1.6 g, 36%) as a colorless oil. LCMS (Method 3, ESI): 354.0 [MH-BOC] + , RT 2.43 minutes.

[0200] Intermediate 56 (3S)-3-Amino-3-(2-chloro-3-iodophenyl)butanoic acid methyl ester hydrochloride To a solution of intermediate 55 (89% by weight) (1.2 g, 2.4 mmol) in 1,4-dioxane (10 mL) was added 4N HCl in 1,4-dioxane (10 mL). The reaction mixture was stirred at room temperature for 46 h and then concentrated in vacuo to give the title compound (89% by weight) (1.04 g, 100%) as a solid. LCMS (Method 3, ESI): 354.0 [MH] + , RT 0.99 min.

[0201] Intermediate 57 tert-Butyl N-[(2-methyl-1,1-dioxothian-4-yl)carbamothioyl]carbamate Prepared from 2-methyl-1,1-dioxothian-4-amine hydrochloride (1.0 g, 5 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 2 thereof) to give the title compound (1.2 g, 78%) as a white solid. LCMS (Method 3, ESI): 321.0 [MH] - , RT 1.50 min.

[0202] Intermediate 58 tert-Butyl (NE)-N-[(4S)-4-(2-chloro-3-iodophenyl)-4-methyl-1-(2-methyl-1,1-dioxothian-4-yl)-6-oxohexahydropyrimidin-2-ylidene]carbamate Prepared from intermediate 57 (1.2 g, 3.7 mmol) and intermediate 56 (1.45 g, 3.7 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 8 thereof) to give the title compound (70% by mass) (1.6 g, 49%) as a white solid. LCMS (Method 3, ESI): 610.0 [MH]+ , RT 2.50 minutes.

[0203] Intermediate 59 tert-Butyl (NE)-N-{(4S)-4-(2-chloro-3-iodophenyl)-1-[(1RS,3RS,4SR)-4-hydroxy-3-methylcyclohexyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from intermediate 7 (880 mg, 3.05 mmol) and intermediate 56 (1.04 g, 2.67 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 8 thereof) to give the title compound (UV purity 60%) (1.14 g, 50%) as a pale yellow solid. LCMS (Method 3, ESI): 576.0 [MH] + , RT 1.36 minutes.

[0204] Intermediate 60 tert-Butyl (NE)-N-[(4S)-1-{(1SR,3SR)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluoro-cyclohexyl}-4-(2-chloro-3-iodophenyl)-4-methyl-6-oxohexahydropyrimidin-2-ylidene]-carbamate Prepared from intermediate 35 (312 mg, 0.74 mmol) and intermediate 56 (450 mg, 1.15 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 8 thereof) to give the title compound (166 mg, 30%) as a white solid. LCMS (Method 3, ESI): 712.2 [MH] + , RT 1.77 minutes.

[0205] Intermediate 61 tert-Butyl N-{[3-(dimethylamino)cyclobutyl]carbamothioyl}carbamate According to the procedure described in WO 2022 / 008639 (for intermediate 2 thereof), 1 ,N 1 -Dimethylcyclobutane-1,3-diamine dihydrochloride (500.0 mg, 4.7 mmol) gave the title compound (240 mg, 33%) as a white solid. LCMS (Method 2, ESI): 274.0 [MH] + , RT 1.12 minutes.

[0206] Intermediate 62 tert-Butyl (NE)-N-{(4S)-4-(2-chloro-3-iodophenyl)-1-[3-(dimethylamino)cyclobutyl]-4-methyl-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from intermediate 61 (200.0 mg, 0.34 mmol) and intermediate 56 according to the procedure described in WO 2022 / 008639 (for intermediate 8 thereof) to give the title compound (410.3 mg), which was used without further purification. LCMS (Method 3, ESI): 561.0 [MH] + , RT 1.31 minutes.

[0207] Intermediate 63 tert-Butyl N-[(1-methylpiperidin-4-yl)carbamothioyl]carbamate Prepared from 4-amino-1-methylpiperidine (0.16 g, 1.24 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 2 thereof) to give the title compound (0.36 g, 95%) as a pale grey solid. LCMS (Method 3, ESI): 274.2 [MH] + , RT 1.47 minutes.

[0208] Intermediate 64 tert-Butyl (NE)-N-[(4S)-4-(2-chloro-3-iodophenyl)-4-methyl-1-(1-methylpiperidin-4-yl)-6-oxohexahydropyrimidin-2-ylidene]carbamate Prepared from intermediate 63 (0.14 g, 3.7 mmol) and intermediate 56 according to the procedure described in WO 2022 / 008639 (for intermediate 8 thereof) to give the title compound (80% by mass) (0.21 g, 73%) as a white solid. LCMS (Method 3, ESI): 561.2 [MH] + , RT 2.61 minutes.

[0209] Intermediate 65 Methyl (3S)-3-(tert-butoxycarbonylamino)-3-[2-chloro-3-(3-chlorophenyl)phenyl]-butanoate Intermediate 55 (1.1 g, 2.3 mmol), 3-chlorophenylboronic acid (1.08 g, 6.9 mmol), Pd(dppf)Cl2 (177.0 mg, 2.3 mmol) and cesium carbonate (2.25 g, 6.9 mmol) were dissolved in 1,4-dioxane (10 mL) and water (1.0 mL). The reaction mixture was stirred at 60 °C under N2 atmosphere for 1.5 h and then filtered through a Celite pad. The filtrate was concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-30% EtOAc in hexanes) to give the title compound (990 mg, 96%) as a pale red oil. LCMS (Method 3, ESI): 338.2 / 340.2 [MH-BOC] + , RT 1.43 minutes.

[0210] Intermediate 66 (3S)-3-Amino-3-[2-chloro-3-(3-chlorophenyl)phenyl]butanoic acid methyl ester hydrochloride To a solution of intermediate 65 (985 mg, 2.25 mmol) in 1,4-dioxane (10 mL) was added 4 M hydrochloric acid in 1,4-dioxane (10 mL). The reaction mixture was stirred at room temperature for 18 h and then concentrated in vacuo to give the title compound (HCl salt) (UV purity 88%) (867 mg, 91%) as a pale yellow powder. LCMS (Method 3, ESI): 338.2 / 340.2 [MH] + , RT 1.19 minutes.

[0211] Intermediate 67 Methyl (3S)-3-(tert-butoxycarbonylamino)-3-[2-chloro-3-(2,4-difluorophenyl)phenyl]-butanoate Prepared from intermediate 55 (1.00 g, 2.08 mmol) and (2,4-difluorophenyl)-boronic acid (0.99 g, 6.25 mmol) following the procedure described for intermediate 65 to afford the title compound (0.75 g, 72%) as a pale yellow semi-solid. H (400 MHz,DMSO-d6)7.47(d,J 7.83 Hz,1H),7.13-7.40(m,6H),3.50(s,3H),3.12-3.28(m,2H),1.69-1.82(m,3H),1.32(s,9H).LCMS(Method 1, ESI):339.90 [MH-BOC] +, RT 2.02 minutes.

[0212] Intermediate 68 3(S)-3-Amino-3-[2-chloro-3-(2,4-difluorophenyl)phenyl]butanoic acid methyl ester hydrochloride Prepared from intermediate 67 (0.7 g, 1.49 mmol) following the procedure described for intermediate 66 to afford the title compound (0.50 g, 82%) as a pale yellow solid. H (400 MHz,DMSO-d6)9.08(br s,3H),7.56-7.63(m,1H),7.47-7.55(m,1H),7.30-7.45(m,3H),7.14-7.25(m,1H),3.58-3 .73(m,1H),3.49(s,3H),3.35-3.42(m,1H),1.80-1.94(m,3H).LCMS(Method 1, ESI):340.17[MH] + , RT 2.08 minutes.

[0213] Intermediate 69 Methyl (3S)-3-(tert-butoxycarbonylamino)-3-[2-chloro-3-(6-cyclopropylpyridin-3-yl)-phenyl]butanoate Prepared from Intermediate 55 (700.0 mg, 1.54 mmol) and 6-cyclopropylpyridin-3-ylboronic acid (327 mg, 6.25 mmol) following the procedure described for Intermediate 65 to give the title compound (430 mg, 63%) as a pale yellow gum. LCMS (Method 5, ESI): 445.2 [MH] + , RT 1.64 minutes.

[0214] Intermediate 70 3(S)-3-Amino-3-[2-chloro-3-(6-cyclopropylpyridin-3-yl)phenyl]butanoic acid methyl ester hydrochloride Prepared from intermediate 69 (430 mg, 0.97 mmol) following the procedure described for intermediate 66 to give the title compound (420 mg, 100%) as a yellow solid. LCMS (Method 5, ESI): 345.1 [MH] + , RT 1.34 minutes.

[0215] Intermediate 71 tert-Butyl N-[(1-cyclopropyl-2-hydroxyethyl)carbamothioyl]carbamate Prepared from 2-amino-2-cyclopropylethanol hydrochloride (112 mg, 2.50 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 2 thereof) to afford the title compound (105 mg, 47%) as a pale yellow oil.

[0216] Intermediate 72 tert-Butyl N-({2-[tert-butyl(dimethyl)silyl]oxy-1-cyclopropylethyl}carbamothioyl)carbamate To a solution of intermediate 71 (100 mg, 0.384 mmol) in DMF (1 mL) was added imidazole (136 mg, 1.98 mmol) and tert-butyldimethylchlorosilane (105 mg, 0.676 mmol). The reaction mixture was stirred at room temperature for 72 h and then purified by flash chromatography (silica, 0-30% EtOAc in hexanes) to give the title compound (93 mg, 63%) as a colorless oil. δ H (400 MHz, CDCl3)10.09(s,1H),7.77(s,1H),3.77-3.96(m,2H),1.51(s,9H),1.19-1.31(m,1H),0.93(s ,9H),0.48-0.71(m,4H),0.29-0.44(m,1H),0.09(s,3H),0.08(s,3H).LCMS(Method 2, ESI):375.0[MH] + , RT 1.82 minutes.

[0217] Intermediate 73 tert-Butyl N-{[(3RS,4SR)-3-hydroxytetrahydropyran-4-yl]carbamothioyl}carbamate Prepared from trans-4-aminotetrahydropyran-3-ol (300 mg, 2.56 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 2 thereof) to give the title compound (500 mg, 67%) as a white solid. LCMS (Method 3, ESI): 277.2 [MH] + , RT 0.76 min.

[0218] Intermediate 74 tert-Butyl N-({(3RS,4SR)-3-[tert-butyl(dimethyl)silyl]oxytetrahydropyran-4-yl}carbamothioyl)carbamate Prepared from intermediate 73 (411 mg, 1.41 mmol) following the procedure described for intermediate 72 to give the title compound (534 mg, 95%) as a colorless oil. LCMS (Method 3, ESI): 391.2 [MH] + , RT 1.47 minutes.

[0219] Intermediate 75 tert-Butyl rac-(2S,4S)-4-(tert-butoxycarbonylcarbamothioylamino)-2-methylpiperidine-1-carboxylate Prepared from tert-butyl rac-(2S,4S)-4-amino-2-methylpiperidine-1-carboxylate (1.5 g, 7.0 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 2 thereof) to give the title compound (2.60 g, 78%) as an off-white solid. LCMS (Method 1, ESI): 372.30 [MH] + , RT 2.31 minutes.

[0220] Intermediate 76 rac-(1S,2S,4S)-4-amino-2-methylcyclohexanol trifluoroacetate A solution of intermediate 5 (801.0 mg, 3.49 mmol) in TFA (2 mL) and DCM (8 mL) was stirred at room temperature for 1 h and then concentrated in vacuo to afford the title compound (800 mg, 94%) as a white solid, which was used without further purification.

[0221] Intermediate 77 tert-Butyl N-{[rac-(1S,3S,4S)-4-hydroxy-3-methylcyclohexyl]carbamothioyl}carbamate Prepared from intermediate 76 (800 mg, 3.49 mmol) according to the procedure described in WO 2022 / 008639 (for intermediate 2 thereof) to give the title compound (810 mg, 52%) as a pale yellow gel. LCMS (Method 3, ESI): 289.2 [MH] + , RT 1.62 minutes.

[0222] Intermediate 78 tert-Butyl N-({rac-(1S,3S,4S)-4-[tert-butyl(dimethyl)silyl]oxy-3-methylcyclohexyl}-carbamothioyl)carbamate Prepared from intermediate 77 (810 mg, 2.81 mmol) following the procedure described for intermediate 72 to afford the title compound (1.12 g, 99%) as a white solid. H (300 MHz,CDCl3)9.54(d,J 8.0 Hz,1H),8.46(s,1H),4.20(dp,J 11.6,3.9 Hz,1H),3.16-3.02(m,1H),2.72(s,1H),2.20-2.02(m,2H),1.85(dq,J 12.6,3.5 Hz,1H),0.86(d,J 7.2 Hz,15H),0.03-0.00(m,9H).LCMS(Method 3, ESI):403.2[MH] + , RT 3.67 minutes.

[0223] Intermediate 79 (6S)-6-[2-chloro-3-(2,4-difluorophenyl)phenyl]-2-imino-6-methyl-3-[(2S*,4S*)-2-methylpiperidin-4-yl]hexahydropyrimidin-4-one To Example 102 (40.0 mg, 0.08 mmol) was added saturated aqueous NaHCO3 (50 mL) at 0° C. The reaction mixture was stirred for 5 min and then extracted with EtOAc (3×25 mL). The organic layer was separated and washed with brine (2×30 mL), then dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (35.0 mg, 90%) as an off-white solid. LCMS (Method 1, ESI): 446.97 [MH] + , RT 0.23 min and 446.97 [MH] + , RT 0.72 min.

[0224] Intermediate 80 (6S)-6-[2-chloro-3-(2,4-difluorophenyl)phenyl]-3-[(2S*,4S*)-1,2-dimethylpiperidin-4-yl]-2-imino-6-methylhexahydropyrimidin-4-one To a solution of intermediate 79 (32.0 mg, 0.07 mmol) and formaldehyde (4.0 mg, 0.13 mmol) in acetic acid (1.5 mL) was added NaBH3CN (8.0 mg, 0.13 mmol). The reaction mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The residue was poured into water (30 mL), basified with aqueous NaHCO3 (15 mL) and extracted with EtOAc (2 x 30 mL). The organic layer was separated and washed with brine (2 x 30 mL) then dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by preparative HPLC to give the title compound (23 mg, 70%) as an off-white solid. δ H (400 MHz, DMSO-d6) 7.31-7.47 (m, 3H), 7.21-7.30 (m, 1H), 7.11 (d, J 2.93 Hz, 1H), 5.79-6.09 (m, 1H), 2.80-2.92 (m, 1H), 2.63-2.75 (m, 1H), 2.14-2.39 (m, 2H), 2.09 (s, 3H), 1.72-1.97 (m, 2H), 1.57 (s, 3H), 0.97 (d, J 5.87 Hz, 3H). Two exchangeable proton signals were not observed, and four proton signals were merged into the solvent peak.

[0225] Intermediate 81 tert-Butyl (NE)-N-[(4S)-1-{(1S*,3S*)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluoro-cyclohexyl}-4-[2-chloro-3-(2-trimethylsilylethynyl)phenyl]-4-methyl-6-oxohexahydro-pyrimidin-2-ylidene]carbamate To a solution of intermediate 39 (100 mg, 0.14 mmol) in THF (5 mL) was added triethylamine (0.06 mL, 0.49 mmol), trimethylsilylacetylene (20.0 mg, 0.25 mmol) and CuI (3.0 mg, 0.014 mmol). The reaction mixture was purged with argon for 10 min and then bis(triphenylphosphine)palladium(II) dichloride (10.0 mg, 0.014 mmol) was added. The reaction mixture was stirred at room temperature for 22 h and then concentrated in vacuo. The residue was diluted with water (40 mL) and extracted with EtOAc (2×40 mL). The organic layer was washed with water (150 mL) and brine (150 mL), then separated, dried over anhydrous sodium sulfate and concentrated in vacuo to give the crude title compound (90.0 mg) as an off-white solid, which was used without further purification. LCMS (Method 1, ESI): 682.3[MH] + , RT 2.98 minutes.

[0226] Intermediate 82 tert-Butyl (NE)-N-[(4S)-1-{(1S*,3S*)-3-[tert-butyl(dimethyl)silyl]oxy-4,4-difluoro-cyclohexyl}-4-(2-chloro-3-ethynylphenyl)-4-methyl-6-oxohexahydropyrimidin-2-ylidene]carbamate To a solution of intermediate 81 (90.0 g, 0.13 mmol) in MeOH (10 mL) was added K2CO3 (20.0 mg, 0.13 mmol). The reaction mixture was stirred at room temperature for 4 h and then concentrated in vacuo. The crude residue was purified by flash chromatography (silica, 0-30% EtOAc in hexanes) to give the title compound (70.0 mg, 89%) as an off-white solid. δ H (400 MHz,DMSO-d6)10.50(s,1H),7.62(d,J 1.47 Hz,1H),7.35-7.37(m,2H),4.68(s,1H),4.45-4.48(m,1H),3.82-3.85(m,1H),3.56(d,J 8.56 Hz,1H),3.20(d,J 8.56 Hz,1H),2.28-2.31(m,2H),1.90-1.92(m,1H),1.75(s,3H),1.48-1.50(m,1H),1.46(s,9H), 1.20-1.22(m,1H),1.01-1.05(m,1H),0.78(s,9H),0.10(s,6H).LCMS(Method 1, ESI):610.27[MH]+ , RT 2.70 minutes.

[0227] Intermediate 83 tert-Butyl (NE)-N-{(4S)-4-[2-chloro-3-(2-trimethylsilylethynyl)phenyl]-4-methyl-1-[(2S,4S)-2-methyltetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from Intermediate 1 (600.0 mg, 1.07 mmol) following the procedure described for Intermediate 81 to give the crude title compound (640.0 mg) as a colorless oil. LCMS (Method 3, ESI): 532.2 [MH] + , RT 3.39 minutes.

[0228] Intermediate 84 tert-Butyl (NE)-N-{(4S)-4-(2-chloro-3-ethynylphenyl)-4-methyl-1-[(2S,4S)-2-methyl-tetrahydropyran-4-yl]-6-oxohexahydropyrimidin-2-ylidene}carbamate Prepared from intermediate 83 (640.0 mg, 1.20 mmol) following the procedure described for intermediate 82 to give the title compound (546.0 mg, 99%) as a colorless foam. LCMS (Method 3, ESI): 460.2 [MH] + , RT 2.58 minutes.

[0229] Intermediate 85 tert-Butyl (NE)-N-[(4S)-1-{(1SR,3SR,4RS)-4-[tert-butyl(dimethyl)silyl]oxy-3-methyl-cyclohexyl}-4-[2-chloro-3-(2-trimethylsilylethynyl)phenyl]-4-methyl-6-oxohexahydro-pyrimidin-2-ylidene]carbamate Prepared from intermediate 11 (80% by weight) (400.0 mg, 0.46 mmol) following the procedure described for intermediate 81 to give the title compound (320.0 mg, 85%) as a colorless oil. LCMS (Method 3, ESI): 660.4 [MH] + , RT 4.42 minutes.

[0230] Intermediate 86 tert-Butyl (NE)-N-[(4S)-1-{(1SR,3SR,4RS)-4-[tert-butyl(dimethyl)silyl]oxy-3-methyl-cyclohexyl}-4-(2-chloro-3-ethynylphenyl)-4-methyl-6-oxohexahydropyrimidin-2-ylidene]carbamate Prepared from intermediate 85 (320.0 mg, 0.48 mmol) following the procedure described for intermediate 82 to give the title compound (208.0 mg, 73%) as a pale pink oil. LCMS (Method 3, ESI): 588.4 [MH] + , RT 3.98 minutes.

[0231] Example 1 to Example 129 General method 1 To a suspension of the particular aryl iodide derivative (1 equiv.) in 1,4-dioxane (0.1 M) and water (1 M) was added the particular boronic acid / ester derivative (2-3 equiv.) and Cs2CO3 (3 equiv.) at room temperature. The reaction mixture was purged with argon for 10 min, then Pd(dppf)Cl2 (0.1 equiv.) was added at room temperature. The reaction mixture was purged with nitrogen for 5 min, then heated at 80 °C in a sealed tube for 1.5 h, then quenched with water and DCM. The phases were separated and the aqueous phase was washed with DCM. The combined organic fractions were concentrated in vacuo. The crude residue was purified by column chromatography. To a solution of the resulting material in 1,4-dioxane was added 4M HCl in 1,4-dioxane (5-10 equiv.). The reaction mixture was stirred at room temperature for 4-22 h. The solution was concentrated in vacuo and then lyophilized using acetonitrile / water (5 mL) to give the title compound (HCl salt). In cases where the particular aryl iodide derivative contained a tert-butyldimethylsilyloxy moiety, after deprotection the crude material was washed with DME and then lyophilized using acetonitrile / water / aqueous HCl to give the title compound (HCl salt).

[0232] General method 2 To a suspension of the particular aryl iodide derivative (1 equiv.) in 1,4-dioxane (0.1 M) and water (1 M) was added the particular boronic acid / ester derivative (2-3 equiv.) and Cs2CO3 (3 equiv.) at room temperature. The reaction mixture was purged with argon for 10 min, then Pd(dppf)Cl2 (0.1 equiv.) was added at room temperature. The reaction mixture was purged with nitrogen for 5 min, then heated at 80 °C in a sealed tube for 1.5 h, then quenched with water and DCM. The phases were separated and the aqueous phase was washed with DCM. The combined organic fractions were concentrated in vacuo. The crude residue was purified by chiral separation to give the two diastereoisomeric isomers. To a solution of each diastereomer in 1,4-dioxane was added 4M HCl in 1,4-dioxane (5-10 equiv.). The reaction mixture was stirred at room temperature for 4-22 h. The solution was concentrated in vacuo and then lyophilized using acetonitrile / water (5 mL) to give the title compound (HCl salt). In cases where the particular aryl iodide derivative contained a tert-butyldimethylsilyloxy moiety, after deprotection the crude material was washed with DME and then lyophilized using acetonitrile / water / aqueous HCl to give the title compound (HCl salt).

[0233] General method 3 A stirred suspension of a particular boronic acid derivative (1 equiv.), a particular aryl iodide derivative (1.1 equiv.) and K2CO3 (3 equiv.) in EtOH (4 mL) and water (1 mL) was purged with argon for 30 min. XPhos Pd G2 (0.05 equiv.) and XPhos (0.2 equiv.) were added at room temperature. The reaction mixture was heated at 80° C. in a sealed tube for 1 h and then concentrated in vacuo. The residue was diluted with brine (50 mL) and extracted with EtOAc (2×100 mL). The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by column chromatography. The resulting solid was redissolved in DCM (5 mL) and TFA (20 equiv.) was added at 0° C. The reaction mixture was stirred at room temperature for 6 h and then concentrated in vacuo. The crude material obtained was purified by washing with diethyl ether (5 mL) and hexanes (10 mL) and then lyophilized using acetonitrile / water (5 mL) to give the title compound (TFA salt).

[0234] General method 4 A stirred suspension of a particular boronic acid derivative (1 equiv.), a particular aryl iodide derivative (1 equiv.) and K3PO4 (3 equiv.) in 1,4-dioxane (6 mL) and water (2 mL) was purged with argon for 30 min. Pd(dppf)Cl2 (0.13 equiv.) was added at room temperature. The reaction mixture was heated at 80° C. in a sealed tube for 1.5 h and then concentrated in vacuo. The residue was diluted with brine (50 mL) and extracted with EtOAc (2×100 mL). The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by column chromatography. The resulting solid was redissolved in DCM (5 mL) and TFA (20 equiv.) was added at 0° C. The reaction mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The crude material obtained was purified by washing with diethyl ether (5 mL) and hexanes (10 mL) and then lyophilized using acetonitrile / water (5 mL) to give the title compound (TFA salt).

[0235] General method 5 To a solution of the particular intermediate (1 equiv.) in DCM (5 mL) was added TFA (1 equiv.) over 10 min at 0° C. The reaction mixture was stirred at room temperature for 3 h and then concentrated in vacuo. The crude residue was purified by trituration with diethyl ether (10 mL) and then dried in vacuo to give the title compound (TFA salt).

[0236] General method 6 A solution of the particular intermediate (1 eq.) in HCl (2M in 1,4-dioxane) (80 eq.) was stirred at room temperature for 4 h. The resulting solution was concentrated in vacuo and then lyophilized with acetonitrile / water (5 mL) to give the title compound (HCl salt).

[0237] General method 7 To a mixture of potassium carbonate (3.0 equiv.) and the particular boronic acid / ester derivative (1.3 equiv.) was added a degassed solution of the particular aryl iodide derivative (1.0 equiv.), XPhos Pd G3 (0.1 equiv.) and XPhos (0.1 equiv.) in 1,4-dioxane / water (4:1) (0.5 mL). The mixture was heated at 90-100 °C for 1.5 h and then filtered. Acetonitrile (0.5 mL) was added and the mixture was then purified by preparative HPLC. To the resulting material was added TFA / DCM (1 mL) and the mixture was stirred at room temperature for 1 h and then concentrated in vacuo. Purification by preparative HPLC afforded the title compound (TFA salt).

[0238] General method 8 To a suspension of the particular aryl iodide derivative (1 equiv.) in 1,4-dioxane (0.1M) and water (1M) was added the particular boronic acid / ester derivative (2-3 equiv.) and Cs2CO3 (3 equiv.) at room temperature. The reaction mixture was purged with argon for 10 min, then Pd(dppf)Cl2 (0.1 equiv.) was added at room temperature. The reaction mixture was purged with nitrogen for 5 min, then heated at 80°C in a sealed tube for 1.5 h, then quenched with water and DCM. The phases were separated and the aqueous phase was washed with DCM. The combined organic fractions were concentrated in vacuo. The crude residue was purified by chiral HPLC to give two, three or four diastereomers. To a solution of each separated diastereomer in 1,4-dioxane was added 4M HCl in 1,4-dioxane (5-10 equiv.). The reaction mixture was stirred at room temperature for 16 h. The solution was concentrated in vacuo and then lyophilized using acetonitrile / water (5 mL) to give the title compound (HCl salt).

[0239] General method 9 To a suspension of the particular aryl iodide derivative (1 equiv.) in 1,4-dioxane (0.1M) and water (1M) was added the particular boronic acid / ester derivative (2-3 equiv.) and Cs2CO3 (3 equiv.) at room temperature. The reaction mixture was purged with argon for 10 min, then Pd(dppf)Cl2 (0.1 equiv.) was added at room temperature. The reaction mixture was purged with nitrogen for 5 min, then heated at 80° C. in a sealed tube for 1.5 h, then quenched with water and DCM. The phases were separated and the aqueous phase was washed with DCM. The combined organic fractions were concentrated in vacuo. The crude material was redissolved in DCM and TFA was added. The mixture was stirred at room temperature for 1-2 h, then concentrated in vacuo. The crude residue was purified by chiral / achiral HPLC to give the title compound (free base).

[0240] General method 10 To a solution of a particular amino ester derivative (1.0 eq.), a particular activated thioester derivative (1.2 eq.) and EDC.HCl (1.5 eq.) in DMF (0.5 M) at 0° C., DIPEA (2.0 eq.) was added. The reaction mixture was stirred at room temperature for 4 h, then diluted with ice-cold water and extracted with EtOAc. The organic layer was separated, washed with brine, then dried over anhydrous sodium sulfate and concentrated in vacuum. The crude material obtained was dissolved in THF (0.1 M) and potassium tert-butoxide (1 M in THF, 1.3 eq.) was added at 0° C. The reaction mixture was stirred at room temperature for 2 h, then quenched with water and extracted with EtOAc. The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuum. The crude residue was purified by chiral preparative HPLC (column: Lux Cellulose-1 150×4.6 mm, 3 μm; column temperature: 35° C.; flow rate: 3 mL / min; method: 3-40% MeOH+0.1% NH4OH over 6.5 min) to give the separated diastereomers. To a solution of each separated diastereomer in 1,4-dioxane (0.1 M) was added 4 M HCl in 1,4-dioxane (5 eq.). The reaction mixture was stirred at room temperature for 18 h. The solution was concentrated in vacuo and then lyophilized using acetonitrile / water (5 mL) to give the title compound (HCl salt).

[0241] General method 11 To a solution of the particular intermediate (0.04 mmol) in DCM (2 mL) was added 4M HCl in 1,4-dioxane (0.08 mmol) at 0° C. The mixture was stirred at room temperature for 30 min and then concentrated in vacuo. The crude residue was washed with a mixture of diethyl ether (2 mL) and n-pentane (5 mL) and dried to give the title compound (HCl salt).

[0242] General method 12 To a solution of the particular aniline derivative (5.0 equiv.) in acetonitrile (0.25 M) was added 2-azido-1,3-dimethylimidazolinium hexafluorophosphate (7.7 equiv.) and DMAP (15.6 equiv.) at room temperature. The reaction mixture was stirred at 50° C. for 21 h, then the particular aryl alkyne derivative (1.0 equiv.), sodium ascorbate (4.5 equiv.), copper sulfate (1.6 equiv.) and water (0.05 M) were added. The reaction mixture was stirred at room temperature for 2 h. The aqueous layer was extracted with EtOAc. The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by column chromatography. The resulting material was dissolved in 4M HCl in 1,4-dioxane (5-10 equiv.). The reaction mixture was stirred at room temperature for 17 h, then concentrated in vacuo. The crude residue was dissolved in MeOH and purified by SCX-2 (1 g cartridge). The resulting material was lyophilized using acetonitrile / water / 0.5N HCl to give the title compound (HCl salt).

[0243] General method 13 To a particular aryl alkyne derivative (1.0 equiv.) and a particular azide derivative (1.0 equiv.) in tert-butanol (0.5 mL) was added a solution of sodium ascorbate (0.4 equiv.) and copper(II) sulfate pentahydrate (0.4 equiv.) in water (0.5 mL) at room temperature. The mixture was stirred at 40° C. for 16 h, then filtered, rinsed with acetonitrile / water (7:3) (0.5 mL), and concentrated in vacuo. The crude material was purified by preparative HPLC. To the resulting purified material was added TFA / DCM (1 mL), and the mixture was stirred at room temperature for 1 h, then concentrated in vacuo, and purified by preparative HPLC to give the title compound (TFA salt).

[0244] Examples 1 to 129 Example 1 was prepared according to general method 1 from intermediate 1 and 5-chloropyridine-3-boronic acid.

[0245] Example 2 was prepared according to general method 1 from intermediate 1 and 2-chloro-4-(trifluoromethoxy)-boronic acid.

[0246] Example 3 was synthesized by the synthesis of Intermediate 1 and (dimethyl)(oxo)[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]imino-λ according to General Method 1. 6 -sulfane.

[0247] Example 4 was prepared according to general method 1 from intermediate 1 and 3-(methylsulfonyl)phenyl-boronic acid.

[0248] Example 5 was prepared according to general method 1 from intermediate 1 and 2-[3-(dimethylphosphoryl)-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

[0249] Example 6 was prepared from Intermediate 1 and Intermediate 3 according to general method 1.

[0250] Examples 7 and 8 were prepared according to general method 2 from intermediate 11 and (3-chloro-phenyl)boronic acid.

[0251] Examples 9 and 10 were prepared from Intermediate 26 and Intermediate 30 according to general method 2.

[0252] Examples 11 and 12 were prepared from Intermediate 26 and Intermediate 28 according to general method 2.

[0253] Example 13 was prepared according to general method 3 from intermediate 31 and 3-(methylsulfonylamino)-phenylboronic acid.

[0254] Example 14 was prepared according to general method 3 from intermediate 31 and 4-(methylsulfonylamino)-phenylboronic acid.

[0255] Example 15 was prepared according to general method 3 from intermediate 1 and 4-chloro-2-fluorophenyl-boronic acid.

[0256] Example 16 was prepared from intermediate 1 and 2,4-dichlorophenylboronic acid according to general method 3.

[0257] Example 17 was prepared from intermediate 1 and 3-chlorophenylboronic acid according to general method 3.

[0258] Example 18 was prepared from intermediate 31 and intermediate 28 according to general method 1.

[0259] Example 19 was prepared from intermediate 31 and intermediate 33 according to general method 1.

[0260] Example 20 was synthesized by the synthesis of Intermediate 31 and (dimethyl)(oxo)[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]imino-λ according to General Method 1. 6 -sulfane.

[0261] Example 21 was prepared according to general method 4 from intermediate 39 and (3-chlorophenyl)boronic acid.

[0262] Example 22 was prepared according to general method 4 from intermediate 41 and (3-chlorophenyl)boronic acid.

[0263] Example 23 was prepared according to general method 1 from intermediate 41 and (5-chloropyridin-3-yl)boronic acid.

[0264] Example 24 was prepared from intermediate 45 according to general method 5.

[0265] Example 25 was prepared from intermediate 48 according to general method 6.

[0266] Example 26 was prepared from intermediate 49 according to general method 6.

[0267] Example 27 was prepared from intermediate 51 according to general method 6.

[0268] Example 28 was prepared from intermediate 52 according to general method 6.

[0269] Example 29 was prepared from intermediate 1 and 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]morpholine according to general method 7.

[0270] Example 30 was prepared from intermediate 1 and 1-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine according to general method 7.

[0271] Example 31 was prepared from intermediate 1 and 6-cyclopropylpyridin-3-ylboronic acid according to general method 7.

[0272] Example 32 was prepared from intermediate 1 and 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole according to general method 7.

[0273] Example 33 was prepared from intermediate 1 and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridazine according to general method 7.

[0274] Example 34 was prepared according to general method 7 from intermediate 1 and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one.

[0275] Example 35 was prepared from intermediate 1 and 4,4,5,5-tetramethyl-2-(naphthalen-1-yl)-1,3,2-dioxaborolane according to general method 7.

[0276] Example 36 was prepared from intermediate 1 and 2-(2-isopropylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane according to general method 7.

[0277] Example 37 was prepared from intermediate 1 and 2-(trifluoromethyl)phenyl-boronic acid according to general method 7.

[0278] Example 38 was prepared from intermediate 1 and 3,4-difluorophenylboronic acid according to general method 7.

[0279] Example 39 was prepared from intermediate 1 and pyridine-4-boronic acid according to general method 7.

[0280] Example 40 was prepared from intermediate 1 and 3-cyanophenylboronic acid according to general method 7.

[0281] Example 41 was prepared from intermediate 1 and pyrimidine-5-boronic acid according to general method 7.

[0282] Example 42 was prepared from intermediate 1 and 2,5-difluorophenylboronic acid according to general method 7.

[0283] Example 43 was prepared from intermediate 1 and 2-methoxy-5-pyridine boronic acid according to general method 7.

[0284] Example 44 was prepared from intermediate 1 and 3,5-difluorophenylboronic acid according to general method 7.

[0285] Example 45 was prepared according to general method 7 from intermediate 1 and (1H-pyrazol-5-yl)boronic acid hydrate.

[0286] Example 46 was prepared from intermediate 1 and 2-chlorophenylboronic acid according to general method 7.

[0287] Example 47 was prepared from intermediate 1 and 2,6-difluorophenylboronic acid according to general method 7.

[0288] Example 48 was prepared from intermediate 1 and 3-(trifluoromethyl)phenyl-boronic acid according to general method 7.

[0289] Example 49 was prepared from intermediate 1 and pyridine-3-boronic acid according to general method 7.

[0290] Example 50 was prepared from intermediate 1 and 2,3-difluorophenylboronic acid according to general method 7.

[0291] Example 51 was prepared from intermediate 1 and 2,4-difluorophenylboronic acid according to general method 7.

[0292] Example 52 was prepared from intermediate 1 and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole according to general method 7.

[0293] Example 53 was prepared according to general method 7 from intermediate 1 and [3-(1H-pyrazol-5-yl)phenyl]-boronic acid hydrate.

[0294] Example 54 was prepared from intermediate 1 and 4-isoxazoleboronic acid pinacol ester according to general method 7.

[0295] Example 55 was prepared from intermediate 1 and (6-chloropyridin-3-yl)boronic acid according to general method 7.

[0296] Example 56 was prepared from intermediate 1 and 1-methylindazole-7-boronic acid according to general method 7.

[0297] Example 57 was prepared from intermediate 1 and 3-chloro-4-pyridineboronic acid according to general method 7.

[0298] Example 58 was prepared from intermediate 1 and 5-methoxypyridine-3-boronic acid according to general method 7.

[0299] Example 59 was prepared from intermediate 1 and 2-methoxypyridine-4-boronic acid according to general method 7.

[0300] Example 60 was prepared from intermediate 1 and 4-cyanophenylboronic acid according to general method 7.

[0301] Example 61 was prepared from intermediate 1 and 2-chloropyridine-3-boronic acid according to general method 7.

[0302] Example 62 was prepared from intermediate 1 and pyrazolo[1,5-a]pyrimidine-3-boronic acid pinacol ester according to general method 7.

[0303] Examples 63, 64, 65 and 66 were prepared from intermediate 58 and 2,4-difluorophenylboronic acid according to general method 8.

[0304] Examples 67, 68 and 69 were prepared according to general method 8 from intermediate 58 and 6-cyclopropylpyridin-3-ylboronic acid.

[0305] Examples 70, 71, 72 and 73 were prepared according to general method 8 from intermediate 58 and 2-(difluoromethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine.

[0306] Examples 74, 75, 76 and 77 were prepared from intermediate 58 and 5-chloropyridine-2-boronic acid according to general method 8.

[0307] Examples 78, 79, 80 and 81 were prepared according to general method 8 from intermediate 58 and [6-(trifluoromethoxy)pyridin-3-yl]boronic acid.

[0308] Examples 82 and 83 were prepared according to general method 8 from intermediate 59 and 5-chloro-pyridine-3-boronic acid.

[0309] Examples 84 and 85 were prepared according to general method 8 from intermediate 60 and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazole.

[0310] Examples 86 and 87 were prepared according to general method 8 from intermediate 60 and 3-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole.

[0311] Examples 88 and 89 were prepared according to general method 9 from intermediate 62 and 2,4-difluorophenylboronic acid.

[0312] Example 90 was prepared from intermediate 64 and 3-chlorophenylboronic acid according to general method 9.

[0313] Example 91 was prepared from intermediate 64 and 2-chloro-4-(trifluoro-methoxy)phenylboronic acid according to general method 9.

[0314] Example 92 was prepared from intermediate 64 and 2,5-dichlorophenylboronic acid according to general method 9.

[0315] Example 93 was prepared from intermediate 64 and 2,4-difluorophenylboronic acid according to general method 9.

[0316] Example 94 was prepared from intermediate 66 and intermediate 72 according to general method 10.

[0317] Examples 95 and 96 were prepared from Intermediate 66 and Intermediate 74 according to general method 10.

[0318] Example 97 was prepared from intermediate 68 and intermediate 22 according to general method 10.

[0319] Examples 98 and 99 were prepared from Intermediate 70 and Intermediate 22 according to general method 10.

[0320] Examples 100 and 101 were prepared from Intermediate 66 and Intermediate 75 according to general method 10.

[0321] Examples 102 and 103 were prepared from Intermediate 68 and Intermediate 75 according to general method 10.

[0322] Examples 104 and 105 were prepared from Intermediate 66 and Intermediate 78 according to general method 10.

[0323] Example 106 was prepared from intermediate 80 according to general method 11.

[0324] Example 107 was prepared from Example 103 following the procedure described for the preparation of Example 106 from Example 102.

[0325] Example 108 was prepared from intermediate 82 and 3-fluoroaniline according to general method 12.

[0326] Example 109 was prepared from intermediate 84 and 2,4,5-trifluoroaniline according to general method 12.

[0327] Example 110 was prepared from intermediate 84 and 2-azido-1,1,1-trifluoro-ethane according to general method 12, omitting the first step.

[0328] Example 111 was prepared from intermediate 84 and 3-fluoroaniline according to general method 12.

[0329] Examples 112 and 113 were prepared according to general method 12 from intermediate 86 and 2,4,5-trifluoroaniline.

[0330] Example 114 was prepared according to general method 13 from intermediate 84 and (2-azidoethyl)dimethyl-amine hydrochloride.

[0331] Example 115 was prepared from intermediate 84 and 3-[(1S)-1-azidoethyl]-pyridine according to general method 13.

[0332] Example 116 was prepared from intermediate 84 and 3-(azidomethyl)-1,1-difluorocyclobutane according to general method 13.

[0333] Example 117 was prepared from intermediate 84 and 3-(azidomethyl)pyridine according to general method 13.

[0334] Example 118 was prepared from intermediate 84 and 1-(2-azidoethyl)pyrrolidine according to general method 13.

[0335] Example 119 was prepared from intermediate 84 and 4-azidopyridine according to general method 13.

[0336] Example 120 was prepared from intermediate 84 and 4-(azidomethyl)pyridine according to general method 13.

[0337] Example 121 was prepared from intermediate 84 and (1-azidoethenyl)benzene according to general method 13.

[0338] Example 122 was prepared from intermediate 84 and azidocyclobutane according to general method 13.

[0339] Example 123 was prepared from intermediate 84 and 1-azido-2-methoxyethane according to general method 13.

[0340] Example 124 was prepared from intermediate 84 and benzyl azide according to general method 13.

[0341] Example 125 was prepared from intermediate 84 and 1-(1-azidoethyl)-2-oxabicyclo[2.1.1]hexane according to general method 13.

[0342] Example 126 was prepared from intermediate 84 and azidobenzene according to general method 13.

[0343] Example 127 was prepared from intermediate 84 and 1-azidobutane according to general method 13.

[0344] Example 128 was prepared from intermediate 84 and 3-[(1R)-1-azidoethyl]-pyridine according to general method 13.

[0345] Example 129 was prepared from intermediate 84 and 4-azidoazepane according to general method 13. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12]

Table 2-13

Table 2-14

Table 2-15

Table 2-16

Table 2-17

Table 2-18

Table 2-19

Table 2-20

Table 2-21

Table 2-22

Claims

1. A compound of formula (I) or a pharma- ceutically acceptable salt thereof: 【Chemistry 1】 During the ceremony, Z represents aryl or heteroaryl, either of which may be optionally substituted by one or more substituents; R １ is C ３－７ Cycloalkyl, C ３－７ Cycloalkyl (C １－６ ) alkyl, aryl (C １－６ ) alkyl, C ３－７ Heterocycloalkyl, C ３－７ Heterocycloalkyl (C １－６ ) alkyl, C ４－９ Heterobicycloalkyl, C ４－９ Spiroheterocycloalkyl or heteroaryl (C １－６ ) alkyl, any of which may be optionally substituted with one or more substituents; R ２ , R ３ and R ４ each independently represents hydrogen, halogen or trifluoromethyl.

2. R １ C ３－７ Cycloalkyl, C ３－７ Cycloalkyl (C １－６ ) alkyl or C ３－７ and heterocycloalkyl, any of which may be selected from the group consisting of halogen, C １－６ Alkyl, hydroxy, oxo, C １－６ Alkoxy and di(C １－６ 2. The compound of claim 1, optionally substituted with 1, 2, or 3 substituents independently selected from: alkylamino.

3. R ３ 3. A compound according to claim 1 or claim 2, wherein represents hydrogen.

4. R ４ A compound according to any one of claims 1 to 3, wherein represents hydrogen.

5. The compound of claim 1 represented by formula (IIA) or a pharma- ceutically acceptable salt thereof: 【Chemistry 2】 During the ceremony, W is O, S(O) ２ , N-R １２ , CH(OH) or CF ２ represents R １１ represents hydrogen, methyl, hydroxy or methoxy; R １２ represents hydrogen or methyl; Z and R ２ is as defined in claim 1.

6. Z represents phenyl, naphthyl, pyrrolo[2,3-b]pyridinyl, pyrazolyl, pyrazolo[1,5-a]-pyrimidinyl, indazolyl, isoxazolyl, benzimidazolyl, triazolyl, pyridinyl, pyridazinyl or pyrimidinyl, any of which may be selected from the group consisting of halogen, cyano, C １－６ Alkyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, difluorocyclobutyl (C １－６ ) alkyl, phenyl, fluorophenyl, trifluorophenyl, benzyl, phenyl (C ２－６ ) alkenyl, morpholinyl, azepanyl, pyrrolidinyl-(C １－６ ) alkyl, 2-oxabicyclo[2.1.1]hexanyl (C １－６ ) alkyl, pyrazolyl, pyridinyl, pyridinyl-(C １－６ ) alkyl, (difluoro) (hydroxy) (C １－６ ) alkyl, (trifluoro) (hydroxy) (C １－６ ) alkyl, oxo, C １－６ Alkoxy, difluoromethoxy, trifluoromethoxy, C １－６ Alkoxy (C １－６ ) alkyl, C １－６ Alkylsulfonyl, di(C １－６ ) alkylamino (C １－６ ) alkyl, C １－６ Alkyl sulfonyl amino, di(C １－６ ) alkylsulfoximino and di(C １－６ 6. The compound according to any one of claims 1 to 5, optionally substituted with 1, 2 or 3 substituents independently selected from: alkylphosphoryl;

7. R ２ A compound according to any one of claims 1 to 6, wherein represents chloro.

8. 2. A compound according to claim 1 as specifically disclosed in any one of the examples.

9. 10. A compound of formula (I) or a pharma- ceutically acceptable salt thereof as defined in claim 1 for use in therapy.

10. 10. A compound of formula (I) or a pharma- ceutically acceptable salt thereof as defined in claim 1 for use in the treatment and / or prophylaxis of malaria.

11. 10. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or a pharma- ceutically acceptable salt thereof in association with a pharma- ceutically acceptable carrier.

12. 13. Use of a compound of formula (I) as defined in claim 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for the treatment and / or prevention of malaria.

13. 13. A method for treating and / or preventing malaria, comprising administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in claim 1 or a pharma- ceutically acceptable salt thereof.

Images